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Abbreviations 
α-ESA   α-eleostearic acid 
AIF   Apoptosis-inducing factor 
APAF1  Apoptotic protease activating factor 1 
APL   Acute promyelocytic leukaemia 
APS   Ammonium Persulfate 
AQP9   Aquaporin 9 
ATO   Arsenic trioxide 
BAX   Bcl-2-associated X protein 
Bcl-2   B-cell lymphoma 
CCND1 or 2  Gene decoding for cyclin D1 or D2 
CDK   Cyclin dependent kinase 
CK1-α   Casein kinase-1-α 
cDNA   Complementary DNA 
CNS   Central nervous system 
CSC   Cancer stem cell 
Ct   Cycle threshold 
ΔCt   Ratio of the Ct-value of gene of interest and the Ct-value of TBP 
ΔΔCt   Ratio of the ΔCt-value of EWS cell and the ΔCt-value of MSCs 
DHH   Desert Hedgehog 
DMEM  Dulbecco’s modified Eagles’s medium 
DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DNA-PK  DNA-dependent protein kinase 
dNTP   Deoxynucleotide 
Doxo   Doxorubicin 
DTT   Dithiothreitol 
ECL   Enhanced chemiluminescent substrate 
ET   Ewing tumour 
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Eto   Etoposide 
EWS   Ewing sarcoma 
FACS   Fluorescence activated cell sorting 
Fas   First apoptosis signal 
FasL   Fas-ligand 
FCS   Fetal calf serum 
FDA   Food and drug administration 
FLI1   Friend leukemia integration 1 transcription factor 
FSC   Forward scatter 
G1 phase  First gap phase 
G2 phase  Second gap phase 
GLI   Glioma-associated oncogenes 
GSK3-ß  Glycogen synthase kinase-3-ß 
Hh   Hedgehog 
HPI1-4  Hedgehog pathway inhibitor 1-4 
IAP   Proteins that inhibit apoptosis 
I-BET151  Inhibitor of the bromodomain and extra terminal domain protein 
IC50 value  Half maximal inhibitory concentration 
IE   Ifosfamide and etoposide 
IGF1R   Insulin-like growth factor 1 receptor 
IHH   Indian Hedgehog 
JNK   c-Jun N-terminal kinase 
K252c   Staurosporinone 
LDH   Lactate dehydrogenase 
MAC   Mitochondrial apoptosis-induced channel 
MMP-9  Matrix metalloproteinase 9 
M-phase  Mitotic phase 
MSC   Mesenchymal stem cell 
MTS 3-(4,5-dimethylthiazol2-yl)-5-(3-carboxyphenyl)-2-(4-
sulfophenyl)-2H-Tetrazoliumsalt 
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NADH   Nicotinamide adenine dinucleotide 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NF-κB   Nuclear factor kappa-light-chain-enhancer of activated B cells  
PARP   Poly (ADP-ribose) polymerase 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
PKA   Protein kinase A 
PML-RAR  Promyelocytic leukaemia retinoic acid receptor 
PNET   Peripheral neuroectodermal tumour 
P/S   Penicillin/Streptomycin 
PTCH   Patched 
PVDF   Polyvinyline fluoride 
qRT-PCR  quantitative Real-time PCR 
RB   Retinoblastoma protein 
RNA   Ribonucleic acid 
ROS   Reactive oxygen species 
RT   Reverse transcriptase 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SHH   Sonic Hedgehog 
SMAC   Second mitochondria-derived activator of caspase 
SMO   Smoothened 
S-phase  Synthesis phase 
SSC   Side scatter 
SUFU   Suppressor of fused 
TBP   TATA-Box Binding Protein 
TBS   Tris-buffered saline 
TBS-T   Tris-buffered saline and Tween 20 
TEMED  Tetramethylethylenediamine 
TGFß   Transforming growth factor beta 
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TNFR   Tumour necrosis factor receptor 
TXNR   Thioredoxin reductase 
VAC   Vincristine, actinomycin D and cyclophosphamide 
VACA   Vincristine, actinomycin-D, cyclophosphamide and doxorubicin 
VDC   Vincristine, doxorubicin and cyclophosphamide 
VIDE   Vincristine, ifosfamide, doxorubicin and etoposide 
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1 Introduction 
1.1 Ewing sarcoma 
1.1.1 Classification and clinical diagnosis of Ewing sarcoma 
Ewing sarcoma (EWS) are mesenchymal tumours, arising from bone but also soft tissue. 
By now, the names Ewing tumour, Askin’s tumour as well as malignant peripheral 
neuroectodermal tumour (PNET) all come under the term of Ewing sarcoma. EWS are 
the second most common bone cancer in children and young adults (Karosas, 2010). The 
most common location is the pelvis, followed by the femur, tibia and fibula, whereas only 
15 % are solely located in soft-tissue. The incidence is higher in males compared to 
females, lying at 1.5:1 (Parkin and Nectoux, 1993). At the time of diagnosis 20 - 30 % of 
the tumours have metastasised to the lung or other parts of the skeletal system (Delattre 
et al., 1994; Le Deley et al., 2010; Potratz et al., 2012). However, other authors such as 
Karosas et al. described that 80 % of the patients have subclinical metastases at the time 
of presentation (Karosas, 2010). Clinical symptoms include local pain, oedema and 
reduced functionality in the concerned body part, but are generally very unspecific and 
often remain undiscovered for a long period of time. In some patients pathological 
fractures may occur (Kashima et al., 2013). 
As EWS are difficultly to distinguish histologically from other small, round blue-cell 
tumours (Desai and Jambhekar, 2010), diagnosis is confirmed by the characteristic 
translocations and immune-histochemical results. The EWS gene, a gene decoding an 
RNA-binding protein is usually fused to the DNA-binding domain of a transcription 
factor of the ETS family involved in proliferation and tumourigenesis. Two translocations 
are very common in the Ewing family of tumours, the EWS-FLI1 gene fusion 
t(11:22)(q24;q12) in 85 - 90 % and the EWS-ERG gene fusion t(21:22)(q22;q12) in         
10 % of the EWS cases (Arvand and Denny, 2001; Delattre et al., 1994). Moreover, the 
most common chimeric gene EWS-FLI1 exists in several different forms. Type 1 results 
from the fusion of EWS exons 1 - 7 with FLI1 exons 6 - 9 occurs in 65 % of all cases and 
is suggested to have a better outcome. The second type, a fusion from EWS exons 1 - 7 
with FLI1 exons 5 - 9 is only seen in about 25 % of the cases (Lin, 1999). Several other 
translocations though on a rare basis have been observed, including EWS-E1AF t(17;22), 
1 Introduction 
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EWS-ETV t(7:22) and EWS-FEV t(2;22) (Mackall et al., 2002). The chimeric EWS-ETS 
proteins are important for the maintenance and progression of EWS. In vitro EWS cells 
expressing antisense EWS-ETS transcripts showed decreased tumour growth and a 
change in their histological appearance (May et al., 1993; Ouchida et al., 1995; Teitell et 
al., 1999). Several studies suggest EWS-FLI1 working as an aberrant transcription factor 
modulating the expression of multiple target genes involved in cell signalling pathways 
such as Hedgehog, Notch-, Wnt-ß-catenin-, TGFß- or IGF1R. Multiple new approaches 
of regulation and inhibition of these pathways are currently under investigation (Taylor 
et al., 2011). 
The exact cell of EWS origin is not yet fully known. Some studies suggest 
neuroectodermal cells as the origin of EWS as peripheral neural crest progenitors can be 
found. Additionally, some EWS cell lines express neuron specific proteins and are able 
to form dendrite similar extensions (Cavazzana et al., 1987; Morrison et al., 1999). 
Another more probable origin of Ewing sarcoma are mesenchymal stem cells (MSC) 
which can differentiate into adipocytes, osteoblasts and chondrocytes (Kolf et al., 2007). 
Cancer stem cells (CSC) which have MSC plasticity were found in EWS (Riggi et al., 
2010) and various studies have shown that suppression or silencing of EWS-FLI1 results 
in expression profiles similar to MSC (induced expression of CD29, CD44, CD54, CD59 
and CD73) (Tirode et al., 2007). The introduction of the EWS-FLI1 fusion protein in 
MSC leads to expression of Ewing sarcoma characteristic proteins (Castillero-Trejo et 
al., 2005; Riggi et al., 2005). Furthermore, different EWS cell lines are able to 
differentiate along the adipogenic and osteogenic lineage upon EWS-FLI1 silencing 
whereas introduction of the fusion protein into MSC isolated from mice inhibits their 
ability to proliferate (Tirode et al., 2007; Torchia et al., 2003). 
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1.1.2 Therapy and prognosis 
Without treatment 5-year survival of EWS-patients is only about 5 - 10 % (Rosen et al., 
1974). Sex, age, tumour size and location, serum LDH concentration, fever or anaemia 
are prognostic variables (Balamuth and Womer, 2010). Therefore, EWS is classified into 
a primarily metastasised and a local type and also the initial tumour size is evaluated for 
treatment decision (Bacci et al., 2006; Oberlin et al., 2001).  
The standard therapy for the local type of EWS currently involves initial chemotherapy 
followed by surgery and/or radiotherapy and subsequent adjuvant chemotherapy with a 
5-year survival rate of over 70 %, whereas therapy of metastasised or relapsed EWS is 
difficult with survival rates of only up to 20 % (Delattre et al., 1994; Esiashvili et al., 
2008; Le Deley et al., 2010). In some cases additional haploidentical stem cell 
transplantation can be necessary and improves the prognosis in metastasised and relapsed 
EWS (Burdach et al., 1993; Koscielniak et al., 2005). 
Chemotherapy usually consists of a combination of 3 or more substances including 
alkylating drugs such as ifosfamide or cyclophosphamide, the anthracycline doxorubicin, 
the topoisomerase inhibitor etoposide or actinomycin D and vincristine (Grier et al., 2003; 
Le Deley et al., 2014; Womer et al., 2012). In the 1960s vincristine was combined with 
actinomycin and cyclophosphamide as well as doxorubicin (VAC + doxorubicin) (Jaffe 
et al., 1976; Rosen et al., 1974). This treatment strategy evolved in North America to an 
alternating treatment of VDC (vincristine-doxorubicin-cyclophosphamide) and IE 
(ifosfamide-etoposide) every two weeks. European studies established the regime of 
VACA (vincristine-doxorubicin-cyclophosphamide-actinomycin) which eventually lead 
to the currently used chemotherapy of VIDE (vincristine-ifosfamide-doxorubicin-
etoposide) (Paulussen et al., 2001; Paulussen et al., 2008). Other studies are adding 
topotecan-cyclophosphamide to the already used VDC-IE therapy (Hunold et al., 2006; 
Saylors et al., 2001). After the initial chemotherapy a complete R0 surgical resection is 
desirable which can be complemented with additional radiotherapy if complete resection 
is not possible (Haeusler et al., 2010). However, radiotherapy in children has decreased 
in value in the past decades due to grieve late effects such as second malignancies and 
growth disturbance (Balamuth and Womer, 2010). 
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In metastasised and relapsed EWS therapy is difficult. Adding IE to VDC treatment or 
increasing doses of doxorubicin, cyclophosphamide and ifosfamide have no better 
outcomes (Grier et al., 2003). Several trials using megatherapy, a therapy combining high 
dose chemotherapy, body irradiation and autological haematopoietic stem cell 
transfusion, could not significantly improve patient survival (Burdach et al., 2003; 
Burdach et al., 2000; Meyers et al., 2001; Oberlin et al., 2006). 
 
1.2 The mechanism of the Hedgehog pathway 
In humans, the Hedgehog (Hh) pathway is responsible for various processes in cells. It is 
important for the development of the embryonic CNS as well as general growth, 
differentiation and self-renewal of cells (Hooper and Scott, 2005; Katoh and Katoh, 2009; 
Michaud and Yoder, 2006; Molofsky et al., 2004; Yu et al., 2009). 
In 1980 the Hh protein was discovered by Nusslein-Volhard and Wieschaus  in Hh-mutant 
drosophila larvae (Drosophila melanogaster) (Nusslein-Volhard and Wieschaus, 1980). 
Today three Hh ligands, namely Sonic Hedgehog (SHH), Indian Hedgehog (IHH) and 
Desert Hedgehog (DHH) are known in mammals (Ingham and McMahon, 2001). The Hh 
pathway is induced by binding of an Hh ligand to its transmembrane receptors Patched 1 
and 2 (PTCH1 or PTCH2). These form a complex with the co-receptor proteins “Cell 
adhesion molecule-related/downregulated by oncogenes” (CDON), the “Brother of Cdo” 
(BOC) and “Growth arrest-specific 1” (GAS1) (Hanna and Shevde, 2016). Thereupon 
PTCH1 releases its suppression of Smoothed (SMO), a G-protein-coupled receptor 
(Carpenter et al., 1998; Teglund and Toftgard, 2010). SMO is localised to the primary 
cilium, an essential sensory cell organelle whose loss results in disorders of kidneys, liver 
and pancreas as well as development defects (Eggenschwiler and Anderson, 2007; 
Michaud and Yoder, 2006). In the primary cilium an intracellular signalling cascade is 
initiated by SMO that results in the stabilisation of the glioma-associated oncogene (GLI) 
transcription factors. The GLI1 protein translocates into the nucleus where it induces the 
transcription of different target genes including Cyclin D1, c-MYC, B-cell lymphoma 2 
(Bcl-2) and SNAIL, all involved in the regulation of cellular proliferation and apoptosis 
resistance (Hooper and Scott, 2005; Riobo and Manning, 2007; Scales and de Sauvage, 
2009; Varjosalo and Taipale, 2008). GLI2 and GLI3 can either act as a repressor or as an 
1 Introduction 
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activator of the Hh pathway, depending on the PKA activity (Hui and Angers, 2011). In 
the presence of Hh ligands GLI2 leads to an activation of GLI1 (Hanna and Shevde, 
2016), whereas GLI3 acts as a transcriptional repressor of Hh target genes in the absence 
of Hh ligands (Kasper et al., 2006; Ng and Curran, 2011). Interestingly, GLI1 targets 
include the genes encoding for PTCH1 and GLI1 itself, leading to a negative feedback of 
the Hedgehog pathway in case of PTCH1 and a positive feedback in case of GLI1 
(Ingham and McMahon, 2001). Figure 1 shows the mechanism of the Hh pathway in 
humans. 
However, GLI1 signalling is not exclusively regulated by upstream ligand availability. 
Several other protein mediators are also involved, such as casein kinase-1-α (CK1-α), 
protein kinase A (PKA), glycogen synthase kinase-3-β (GSK3-β) or the GLI1-inhibitor 
“suppressor of fused” (SUFU) (Kogerman et al., 1999; Stone et al., 1999). 
 
Figure 1: Mechanism of the Hh pathway. Interaction of the receptors SMO and PTCH regulating GLI 
activity A: in the absence of Hh ligands and B: with Hh ligands binding to PTCH. (Buller et al., 2012) 
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1.3 The role of the Hedgehog pathway in tumour genesis and 
progression 
Hyperactive Hh signalling has been identified in different malignancies such as 
pancreatic, colon, gastric, lung, breast and prostate cancer, multiple myeloma and 
different leukaemias. Furthermore, specific mutations in proteins involved in Hh pathway 
regulation have been found in basal carcinoma and medulloblastoma (McMahon et al., 
2003; Scales and de Sauvage, 2009). GLI1 and GLI2 are transcription factors capable of 
activating their targets. However, GLI2 is the primary mediator of transcriptional 
activation, initiating GLI1 transcription, which subsequently activates its target genes 
(Bai et al., 2002; Ikram et al., 2004; Katoh and Katoh, 2009; Thiyagarajan et al., 2007). 
Both GLI1 and GLI2 are oncogenes, inducing transformation and tumourigenesis (Kasper 
et al., 2006; Katoh and Katoh, 2009; Kinzler et al., 1987; Zhang et al., 2013). Several 
studies confirm that an overexpression of Hh ligands (SHH, IHH and DHH) or GLI1 can 
lead to cancer formation and progression (Pressey et al., 2011). Moreover, decreased 
PTCH1 activity leads to apoptosis resistance in a murine model (Hahn et al., 1998; 
Kappler et al., 2003). 
In addition to proliferation and inhibition of apoptosis tumour progression is also marked 
by angiogenesis and the ability to metastasise. Lee et al. found Hh pathway activation to 
elevate the levels of the angiogenic factors angiopoetin 1 and 2 (Lee et al., 2007). 
Moreover, in small cell lung cancer Hh signalling has also been found to be a potent 
regulator of angiogenesis (Velcheti, 2007). Metastasis is regulated through cell adherence 
on the one hand and mobility on the other hand. The Hh pathway is known to decrease 
the number of tight junctions and the expression of E-cadherin, a transmembrane protein 
forming adherence junctions and increasing levels of Snail Family Zinc Finger 1 
(SNAI1), which leads to a repression of E-cadherin (Davidson and Sukumar, 2005; Li et 
al., 2006). SHH and GLI1 can also promote invasion by activating matrix 
metalloproteinase 9 (MMP-9) expression in oral squamous cell carcinoma (Fan et al., 
2014) and gastric cancer (Yoo et al., 2011). MMP-9 is a protein important for the 
degradation of extracellular matrix (Ohnishi et al., 1998). 
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1.3.1 Effect of the Hedgehog pathway on proliferation 
Proliferation of cells is regulated by a complex cell cycle consisting of the mitotic phase 
(M-phase) and the interphase. During the M-phase the cytoplasm and DNA is divided, 
whereas during the interphase the cell is prepared for the next division and DNA is 
replicated. Proliferation is initiated by external stimulating signals and begins with a gap 
phase (G1) where cells grow and synthesise proteins. This is followed by the S-phase 
where DNA is replicated. Before entering the next phase a control point ensures that the 
cell is ready for DNA replication during the S-phase. After replication the cell is prepared 
for division during a second gap phase (G2), ending with another control point where 
eventual mistakes or damages during replication can be repaired (Elledge, 1996). Vital 
for the correct regulation of the cell cycle are cyclins and cyclin dependent kinases (CDK) 
both forming active complexes which can regulate cell cycle progression and are specific 
for each phase (Gillett and Barnes, 1998; Nigg, 1995). 
If components of the cell cycle are dysregulated this may lead to uncontrollable 
proliferation and tumour formation. Besides, cyclins and CDKs, typical cell cycle 
inhibitors such as the retinoblastoma protein (RB) or p53 can be mutated (Champeris 
Tsaniras et al., 2014). Furthermore, the dysregulation of other cellular pathways can also 
lead to an aberrant progression of the cell cycle. One of these is the Hh pathway as several 
studies suggest. Recently, Sun et al. described that inhibition of GLI1 in chondrosarcoma 
results in a G2/M arrest of the tumour cells (Sun et al., 2014). Another study found the 
genes CCND1 and CCND2, encoding for cyclin D1 and D2, respectively to be regulated 
by GLI1 (Katoh and Katoh, 2009). Cyclin D1 and D2 form cyclin-CDK complexes with 
CDK4 and CDK6 initiating the entry into S-phase (Sherr and Roberts, 1999). An 
interaction between the Hh pathway and the tumour suppressor p53 has been suggested 
but still needs further investigation (Malek et al., 2011). However, Lu et al. found SHH 
to initiate regeneration in cochlear hair cells through downregulation of Retinoblastoma 
protein (RB) (Lu et al., 2013). 
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1.3.2 Effect of the Hedgehog pathway on apoptosis 
In contrast to uncontrolled cell disruption during necrosis, apoptosis is the programmed 
cell death producing cell fragments so called apoptotic bodies that are completely 
removed by phagocytic cells without causing inflammation (Kurosaka and Kobayashi, 
2003; Savill and Fadok, 2000). Apoptotic signals such as e.g. heat, radiation, nutrient 
deprivation, hypoxia, membrane damage or infection cause regulatory proteins to initiate 
the apoptotic cascade ultimately leading to caspases activation and cell death (Norbury 
and Hickson, 2001). Two main forms of apoptosis induction are currently distinguished, 
the intrinsic and the extrinsic pathway. However, both pathways are linked and influence 
each other (Igney and Krammer, 2002). Intrinsic apoptosis, also known as the 
mitochondrial mediated form, is induced by mitochondrial membrane permeabilisation 
releasing second mitochondria-derived activator of caspase (SMAC) and cytochrome c. 
SMACs deactivate proteins that inhibit apoptosis (IAP) and thereby induce an effector 
caspase cascade (Elmore, 2007). Cytochrome c forms a complex with the apoptotic 
protease activating factor 1 (APAF1) activating caspase 9 thus also inducing an effector 
caspase cascade (Elmore, 2007; Fesik and Shi, 2001; Tsujimoto, 1998). The extrinsic 
apoptotic pathway is mediated through receptors of the tumour necrosis factor receptor 
(TNFR) family. Binding of the cytokine TNF-α to TNFR1 or the transmembrane protein 
FasL (Fas ligand) to the Fas (First apoptosis signal) receptor results in cleavage of 
procaspase 8 to the active caspase 8 leading to the induction of an effector caspase cascade 
(Ramaswamy et al., 2009; Wajant, 2002). The effector caspases 3, 6 and 7 ultimately 
induce cell shrinkage, chromatin condensation, nuclear DNA fragmentation, cell 
organelle degradation and vesicle formation (Green, 2011). 
Several studies have found the Hh pathway to be involved in apoptosis inhibition. Both 
GLI1 and GLI2 seem to induce high levels of the anti-apoptotic protein Bcl2 inhibiting 
the formation of a mitochondrial apoptosis-induced channel (MAC) through which 
cytochrome c is released (Dejean et al., 2006; Katoh and Katoh, 2009). Athar et al. also 
found GLI proteins to lead to a decrease of pro-apoptotic proteins such as Fas (Athar et 
al., 2004) and in ameloblastoma  the therapeutic approach of neutralising SHH with 
antibodies resulted in a decrease of Bcl2 and an increase of Bcl2-associated X protein 
(BAX) which is implicated in MAC formation (Kanda et al., 2013). 
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1.3.3 The Hedgehog pathway in Ewing sarcoma 
The fusion protein EWS-FLI1 is essential for EWS and has influence on various 
signalling pathways involved in apoptosis and proliferation. A direct transcriptional target 
of EWS-FLI1 is GLI1 as experimental modulation of EWS-FLI1 expression and analysis 
of the interaction between EWS-FLI1 and GLI1 promoter by ChIP assay showed 
(Beauchamp et al., 2009). The upstream protein PTCH1 is also upregulated by            
EWS-FLI1, whereas GLI2, GLI3 and the GLI1 inhibitor SUFU are not altered in any way 
(Zwerner et al., 2008). The increased activity of GLI1 appears to be independent of 
upstream stimulation mediated by the Hh pathway as SHH and IHH are hardly 
upregulated and the inhibition of SMO has no measurable effect on GLI1 activation in 
EWS (Joo et al., 2009; Zwerner et al., 2008). 
 
1.4 Inhibition of the Hedgehog pathway 
Different components of the Hh pathway can be targeted by drugs depending on the cause 
of the abnormal Hh pathway activation. In medulloblastoma (McCall et al., 2007) as well 
as pancreas and prostate carcinoma (Farooqi et al., 2011; Mo et al., 2011) inhibition of 
the Hh pathway leads to lower levels of Bcl-2 and therefore a higher rate of apoptosis. 
One of the targets most focused on in the last years is SMO. Several SMO inhibitors 
including sonidegib (LDE225) are in different phases of clinical development (Burness, 
2015; Rodon et al., 2014) or the already approved for treatment like vismodegib of 
metastatic basal cell carcinoma (Rudin, 2012).  
Downstream of SMO the GLI transcription factors can be targeted by several natural 
compounds such as staurosporinone (K252c), zerumbone, arcriaflavin C and physalin B 
and F (Hosoya et al., 2008) as well as the synthetic products HPI1-4, GANT58, GANT61, 
Arsenic trioxide (ATO), GlaB, JQ1 and I-BET151 (Beauchamp et al., 2011; Gonnissen 
et al., 2015). As the fusion protein EWS-FLI1 directly leads to an activation of GLI in 
EWS, two different GLI inhibitors, GANT61 and ATO were used in this work.  
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1.4.1 GANT61 
GANT61 is a small molecule that was first identified in a cell-based screen for inhibitors 
of GLI1 and GLI2-mediated transcription in human prostate cancer xenografts where it 
was described to inhibit both the GLI1 and GLI2 dependent transcription as well as 
binding of GLI1 to the DNA resulting in lower levels of GLI protein expression (Lauth 
et al., 2007). GANT61 directly binds GLI1 in a groove between zinc fingers 2 and 3 
(Agyeman et al., 2014). Through inhibition of GLI1-DNA binding and therefore 
inhibition of Hh target gene expression, GANT61 leads to a cell cycle arrest, increased 
apoptosis and inhibition of DNA damage repair as well as cell migration (Gonnissen et 
al., 2015). Recently Lim et al. found GANT61-induced apoptosis to be dependent on 
mitochondrial release of reactive oxygen species (ROS), which means that GANT61 also 
acts through the induction of oxidative stress (Lim et al., 2015). 
Since its discovery in 2007 GANT61 has been tested in several in vitro and in vivo studies. 
A significant decrease of tumour growth in animal studies has been shown for prostate 
(Lauth et al., 2007), pancreatic (Fu et al., 2013), hepatocellular (Wang et al., 2013), colon 
(Mazumdar et al., 2011) and lung cancer (Huang et al., 2014) as well as neuroblastoma 
(Wickström et al., 2013) and rhabdomyosarcoma (Srivastava et al., 2014). Therefore, 
GANT61 is currently in preclinical studies for therapy of rhabdomyosarcoma, 
neuroblastoma, leukaemia, colon, pancreatic and prostate cancer (Agyeman et al., 2014). 
 
Figure 2: Molecular structure of GANT61 
(Reagents Direct, 2010). 
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1.4.2 ATO 
An effect of ATO in acute promyelocytic leukaemia (APL) was found in the early 1970s 
and is today FDA-approved for patients with APL as second line therapy after all-trans 
retinoic acid thereby often inducing remission with survival rates of about 90 % (Hu et 
al., 2009; Niu et al., 1999). 
Different mechanisms of ATO induced tumour inhibition have been found. In APL the 
degradation of the promyelocytic leukaemia retinoic acid receptor α (PML-RARα) fusion 
protein by ATO leads to tumour growth inhibition. Here, ATO binds to cysteine residues 
of the zinc fingers (Nasr et al., 2008). As GLI proteins also belong to the zinc finger group 
of proteins a similar mechanism of inhibition has been postulated (Kinzler et al., 1988). 
Direct GLI2 inhibition by ATO was demonstrated (Kim et al., 2010). ATO inhibits the 
translocation of GLI2 in and out of the primary cilium, subsequently leading to gradation 
of GLI2. Beauchamp et al. on the other hand described inhibition of GLI1 transactivation 
in EWS cell lines after ATO treatment (Beauchamp et al., 2011). Furthermore, cell lines 
with high levels of GLI1 are more sensitive to ATO (Beauchamp et al., 2011). Additional 
targets of ATO in other tumour types are Nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), thioredoxin reductase (TXNR) and c-Jun N-Terminal Kinase 
(JNK) (Cavigelli et al., 1996; Hayashi et al., 2002; Kapahi et al., 2000; Lu et al., 2007; 
Mann et al., 2006). However, NF-κB and JNK do not seem to be targets of ATO in EWS 
(Beauchamp et al., 2011; White and Burchill, 2008). 
In vitro tests have already shown ATO cytotoxicity against EWS cell lines leading to 
inhibition of migration and invasion (Zhang et al., 2012). An in vivo testing of ATO in 
EWS xenograft models and medulloblastoma allograft models also demonstrated its 
efficacy (Beauchamp et al., 2011; Kim et al., 2010). However, in another in vivo study by 
Smith et al. using EWS xenografts ATO showed no significant effect (Smith et al., 2012). 
 
Figure 3: Molecular structure of 
Arsenic trioxide (Fisher Scientific, 
2015). 
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1.5 Cytostatics in tumour therapy 
Chemotherapy in EWS consists mostly of a combination of three or more cytostatics such 
as alkylating substances (ifosfamide or cyclophosphamide), the anthracycline 
doxorubicin, the topoisomerase inhibitor etoposide, actinomycin D and vincristine (Grier 
et al., 2003; Le Deley et al., 2014; Womer et al., 2012). 
1.5.1 Etoposide 
Etoposide was first introduced in 1971 and is now part of the first-line treatment against 
testicular cancer (Loehrer, 1991; Nichols, 1992), small cell lung cancer (Johnson et al., 
1991) as well as Kaposi’s sarcoma (Schwartsmann et al., 1997). It also shows established 
activity in various lymphoma, neuroblastoma, sarcoma and ovarian cancer (Aisner and 
Lee, 1991). For EWS etoposide was recommended for first-line treatment in 2003 (Grier 
et al., 2003). 
Its origin lies in a plant-based toxin, the podophyllotoxin, which can be obtained from the 
roots and rhizomes of the Podophyllum emodi growing in the Himalaya region, and 
Podophyllum peltatum native to North America (Imbert, 1998; Kelly and Hartwell, 1954). 
Podophyllotoxin was first synthesised in 1966 (Gensler and Gatsonis, 1966) and showed 
promising antimitotic and cytotoxic effects in clinical studies due to the inhibition of 
tubulin to assemble to microtubules during the metaphase (Sackett, 1993). However, the 
anticancer properties were accompanied by severe gastrointestinal side effects and other 
toxicities (Imbert, 1998; Kelly and Hartwell, 1954; Stahelin and von Wartburg, 1989). 
Derivates with less toxic effect were synthesised so that in 1968 a semisynthetic 
podophyllotoxin glycoside (etoposide) was found by Kuhn and van Wartburg (Kuhn and 
von Wartburg, 1968). In clinical trials beginning in 1971, the anti-tumour activity of 
etoposide was proven accompanied by overall modest side effects (Jensen et al., 1990; 
Muggia et al., 1971; Nissen et al., 1972). Figure 4 shows the molecular structure of 
etoposide. 
In contrast to podophyllotoxin, etoposide leads to a cell cycle arrest in the G2-phase 
(Loike and Horwitz, 1976b; Stahelin, 1973). This difference is also reflected in studies to 
chemo-resistance where cells resistant to tubulin polymerization inhibitors (like 
podophyllotoxin) were still sensitive to etoposide (Gupta, 1983). The cytotoxic 
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mechanism of etoposide is based on an accumulation of DNA double strand breaks in the 
nucleus which leads to a high activity of the DNA-dependent protein kinase (DNA-PK). 
DNA-PK activates p53, a protein responsible for cell cycle arrest and apoptosis induction 
(Karpinich et al., 2002). In its activated form p53 upregulates pro-apoptotic proteins, 
resulting in cytochrome c release from the mitochondria and subsequent intrinsic 
apoptosis (Karpinich et al., 2002; Siliciano et al., 1997). 
Permanent cleavage of DNA double strands is based on an interaction of etoposide with 
topoisomerase II, which is important for the unwinding and overwinding of DNA during 
transcription and replication. Usually, topoisomerase II cleaves and reseals DNA double 
strands (Watt and Hickson, 1994). When interacting with etoposide the re-ligation of 
these DNA breaks is inhibited leading to apoptosis and ROS as well as trapped 
topoisomerase I-DNA complexes (Sordet et al., 2006). The application of etoposide as an 
anti-cancer drug relies on a higher amount of topoisomerase II in proliferating cells 
compared to quiescent cells and therefore a more distinct cytotoxic effect of etoposide in 
neoplastic tissue (Hasegawa et al., 1993; Kimura et al., 1994; Sinha, 1995). 
Though initially efficient, etoposide resistance has been observed in cancer cells due to 
alterations in the topoisomerase II enzyme or multidrug resistances (Matsumoto et al., 
1999). Furthermore, some side-effects like myelosuppression, leukopenia, thrombopenia 
or secondary leukaemia can occur (Kobayashi and Ratain, 1994; Kumar, 1993).  
 
Figure 4: Molecular structure of 
etoposide (Medicines Complete, 2016). 
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1.5.2 Doxorubicin 
Doxorubicin was originally isolated from the microorganism Streptomyces peucetius var. 
caesius after mutagenic treatment in 1968 (Arcamone et al., 1969). It is a class I          
DNA-binding anthracycline which inhibits nuclear DNA replication and RNA synthesis 
(Potmesil et al., 1984). Di Marco et al. (1969) were the first to show its highly potent 
tumour growth inhibition in ascites carcinoma, lymphoma, myeloma and sarcoma. The 
effect of doxorubicin was stronger compared to the previously discovered daunorubicin 
in the early 1960s (Casazza et al., 1971). Clinical trials ensued where the anti-tumour 
properties were confirmed especially in Ewing sarcoma and neuroblastoma. In addition, 
Wilms’ tumours, soft tissue sarcomas and lymphomas were highly sensitive to 
doxorubicin (Bonadonna et al., 1969; Bonadonna et al., 1970). However, cardiotoxic 
side-effects ranging from well manageable cardiomyopathy to life-threatening heart 
failure but also alopecia, stomatitis, myelosuppression and gastroenteritis, limit the 
application of doxorubicin (Lown, 1993; Minow and Gottlieb, 1975). Therefore, clinical 
administration favours a combination therapy, rather than treatment with doxorubicin 
alone to achieve greater response rates at lower concentrations leading to less severe 
adverse effects (Benjamin et al., 1977; Bonadonna et al., 1977). Today doxorubicin is 
part of the first-line therapy of various tumours including Ewing sarcoma (Weiss, 1992). 
The most probable mechanism of doxorubicin induced cell death is similar to etoposide. 
The DNA intercalation leads to inhibition of topoisomerase II which results in double 
strand DNA breaks and as described in chapter 1.5.1 Etoposide for etoposide this 
ultimately induces apoptosis (Minotti et al., 2004; Tewey et al., 1984). An additional 
mode of action has been described by Cullinane and Phillips. Instead of intercalating in 
DNA, doxorubicin can also form drug-DNA adducts, acting as inter-strand crosslinks in 
the DNA duplex (Cullinane and Phillips, 1990). Doxorubicin-DNA adduct formation is 
dependent on the addition of formaldehyde which has been shown to enhance cytotoxicity 
of doxorubicin. Thus, a combination treatment with doxorubicin and formaldehyde 
releasing drugs might be promising in future tumour therapy (Cutts et al., 2001; Cutts et 
al., 2015; Swift et al., 2006; Taatjes et al., 1996). 
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Figure 5: Molecular structure of 
doxorubicin. (Department of Chemistry & 
Biochemistry UCLA, 2015) 
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2 Materials and Methods 
2.1 Methods 
2.1.1 Cells 
All experiments were performed with the three EWS cell lines A673, RD-ES and           
SK-N-MC. As a control bone marrow derived mesenchymal stem cells (MSC-2014-7) 
from a healthy donor were used. 
A673 
A673 were obtained from CLS Cell Lines Service GmbH (Eppelheim, Germany) and 
were cultivated in Dulbecco’s modified Eagles’s medium (DMEM) with GlutaMAX     
4.5 g/l D-glucose (Gibco, Life Technologies, Darmstadt, Germany). The medium was 
supplemented with 10 % fetal calf serum (FCS) and 1 % Penicillin/Streptomycin (P/S). 
A673 cells were diluted between 1:10 and 1:25 and detached from flasks with 1 % trypsin. 
The cell line was established from a 15 year old female with a soft tissue sarcoma and 
shows specific characteristics of EWS which lead to its characterization as Ewing tumour 
(ET). Both the typical t(11;22) translocation and the EWS-FLI1 fusion protein type I were 
found (Giard et al., 1973; Martinez-Ramirez et al., 2003). Moreover, the cells have a    
non-functional p53 and express neither p16 nor p14 (May et al., 2013). The adherent cells 
show a polygonal growth (Figure 6). 
 
Figure 6: Light micrographs of A673 cells 
during routine cell culture. 
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RD-ES 
The cell line RD-ES was obtained from CLS Cell Lines Service GmbH (Eppelheim, 
Germany) and was cultivated in RPMI 1640 with L-glutamine (Gibco, Life Technologies, 
Darmstadt, Germany). The medium was supplemented with 15 % FCS and 1 % P/S. Cells 
were detached with 1 % trypsin and diluted between 1:8 and 1:20 during culture. The cell 
line was established by G. Marshall and M. Kirchen from a 19 year old Caucasian male 
with primary osseous EWS located in the humerus (CLS, 2016). RD-ES cells are               
20 - 25 µm in diameter and grow in small loosely attached clusters (Figure 7). Expression 
of a EWS-FLI1 fusion protein of the type II has been established (Lin et al., 1999). 
 
Figure 7: Light micrographs of RD-ES cells 
during routine cell culture. 
SK-N-MC 
SK-N-MC were obtained from ATCC (Manaddas, VA, USA) and were maintained in 
RPMI 1640 with L-glutamine (Gibco, Life Technologies, Darmstadt, Germany). Medium 
was supplemented with 15 % FCS and 1 % P/S. For cell culture SK-N-MCs were diluted 
between 1:8 and 1:15 and detached with 1 % trypsin. The cell line was established by      
J. L. Biedler from a 12 year old Caucasian female with the initial diagnosis of 
neuroepithelioma (Biedler et al., 1973). Today, it is approved that this cell line was 
established from the retroorbital metastasis of an Askin’s tumour, a peripheral PNET. 
Before isolation of the cell line the patient received chemotherapy including vincristine, 
cyclophosphamide, doxorubicin and actinomycin D. The cells express a EWS-FLI1 
fusion protein I and have a non-functional p53 (May et al., 2013). SK-N-MCs grow 
adherent and appear as loosely attached monolayers (Figure 8). 
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Figure 8: Light micrographs of SK-N-MC 
cells during routine cell culture. 
Control cells (MSC-2014-7) 
Mesenchymal stem cells (MSC) are the most probable origin of EWS (Kolf et al., 2007). 
MSC were isolated and propagated as described by Battula and Treml from a healthy 
donor (Battula et al., 2009). To confirm their origin they were differentiated towards 
chondrocytes, adipocytes and osteocytes. MSC were cultivated in DMEM low Glucose 
(1 g/l), supplemented with 25 ml fresh frozen plasma, 25 ml thrombocyte concentrate, 
1ml heparin sodiumsalt (2 IE), 5 ml L-glutamine (2 mM) and 5 ml P/S per 500 ml. Fresh 
frozen plasma and thrombocyte concentrate were stored at -70 °C. After thawing, both 
were centrifuged at 3000 rcf for 30 min and the supernatants were added to the medium. 
Cells were split 1:1 or 1:2 upon reaching 90 % confluency for up to six serial passages 
using accutase (Figure 9). 
 
Figure 9: Light micrographs of MSC-2014-7 cells during routine cell culture. 
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2.1.2 Cell culture 
Table 1: Cell culture 
Name Material 
Number 
Manufacturer 
Accutase A6964 Sigma-Aldrich, St. Louis, Missouri, USA 
DMEM high glucose 
(4.5 g/l) + GlutaMax-I 
31966-021 Gibco, Life Technologies, Darmstadt, 
Germany 
DMEM + low Glucose 
(1 g/l), no glutamine 
11880-028 Gibco, Life Technologies, Darmstadt, 
Germany 
RPMI 1640 21875-091 Gibco, Life Technologies, Darmstadt, 
Germany 
DPBS 14190-094 Gibco, Life Technologies, Darmstadt, 
Germany 
Fetal Calf Serum 
(FCS) 
S0615 Biochrom, Berlin, Germany 
Fresh Frozen Plasma 15900014 Blood bank from University Hospital, 
Tübingen, Germany 
Heparin sodium salt A3004 AppliChem GmbH, Darmstadt, Germany 
L-Glutamine G7513-
100ML 
Sigma-Aldrich, St. Louis, Missouri, USA 
Penicillin/Streptomycin P4333 Sigma-Aldrich, St. Louis, Missouri, USA 
Platelet concentrate 15900011 Blood bank from University Hospital, 
Tübingen, Germany 
Trypsin-EDTA T4174m Sigma-Aldrich, St. Louis, Missouri, USA 
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2.1.3 Cytostatics and Inhibitors 
 
Table 2: Cytostatics and Inhibitors 
Name Material Number / 
Description 
Manufacturer 
ATO Trisenox Pharmacy of University 
Hospital, Tübingen 
Doxorubicin S1208 Selleckchem, Houston, 
Texas, USA 
Etoposide E1383/ VP-16-213 Sigma-Aldrich, St. Louis, 
Missouri, USA 
GANT61 Ab120904 Abcam, Cambridge, UK 
 
Table 3: Stock solutions 
Inhibitor Solvent Concentration of stock 
solution 
ATO H2O (ultrapure, autoclaved) 0.1 mM 
Doxorubicin DMSO 5 mM 
Etoposide DMSO 5 mM 
GANT61 DMSO 5 mM 
 
2.1.4 Equipment 
 
Table 4: Devices 
Name Material Number / 
Description 
Manufacturer 
Balance (0.5 – 4100 g) 6J4100-2M Kern, Balingen, Germany 
Balance (10 mg – 220 g) ABJ220_4M Kern, Balingen, Germany 
Benchtop centrifuge Centrifuge 5424 R Eppendorf, Hamburg, 
Germany 
Centrifuge 5804 R Eppendorf, Hamburg, 
Germany 
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Electric pipette Pipetus akku Hirschmann Laborgeräte, 
Eberstadt, Germany 
Electrophoresis chamber Mini PROTEAN® Tetra 
Cell 
Bio-Rad Laboratories 
GmbH, Munich, Germany 
Flow cytometer LSR II Becton Dickinson, 
Franklin Lakes, New 
Jersey, USA 
Freezer (-20 °C)  Liebherr, Bulle, 
Switzerland 
Freezer (-70 °C)  GFL, Burgwedel, 
Germany 
Fridge (4 °C) 30 GT/N1201V Haier, Qingdao, China 
Gel casting station Mini PROTEAN® Tetra 
Handcast system 
Bio-Rad Laboratories 
GmbH, Munich, Germany 
Horizontal shaker MTS 4 IKA, Staufen, Germany 
Incubator CB 150 Binder, Tuttlingen, 
Germany 
Magnetic stirrer MAG RCT IKA, Staufen, Germany 
Microplate reader EL 800 Bio-Tek, Winooski, 
Vermont, USA 
Microscope Fluovert FS Leica, Wetzlar, Germany 
Microscope DM IRBE Leica, Wetzlar, Germany 
Multichannel pipette Xplorer plus Eppendorf, Hamburg, 
Germany 
Multidispenser Handy Step Bran, Wertheim, Germany 
Neubauer counting 
chamber 
T=0.1 mm; 0.0025 mm2 Karl Hecht GmbH & Co 
KG, Sondheim, Germany 
pH-meter Five easy FE 20 Mettler-Toledo, 
Greifensee, Switzerland 
Power Supply PowerPac™ Basic,  
164-5050 
Bio-Rad Laboratories 
GmbH, Munich, Germany 
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Photometer NanoDrop 3300 Thermo Scientific, 
Waltham, Massachusetts, 
USA 
qRT-PCR machine CFX96 Real-time system, 
C1000 Thermal Cycler 
Biorad, Hercules, 
California, USA 
Single channel pipette Research Plus Eppendorf, Hamburg, 
Germany 
Sterile workbench  BDK, Sonnenbühl-
Genkingen, Germany 
Thermomixer Thermomixer Comfort 
5355 
Eppendorf, Hamburg, 
Germany 
Ultrasonic bath Transsonic 450 Ela Schmidbauer GmbH, 
Singen, Germany 
Vortex mixer REAXtop Heidolph, Schwabach, 
Germany 
Waterbath WB 22 Memmert, Schwabach, 
Germany 
Westernblot developing 
machine 
Curix 60 Processor Agfa-Gevaert N. V., 
Mortsel, Belgium 
 
Table 5: Disposables 
Name Material Number Manufacturer 
Culture plates 
6-well plates 
12-well plates 
 
657160 
665102 
 
Greiner Bio-One, 
Frickenhausen, Germany 
96-well plates, F-bottom 655180 Greiner Bio-One, 
Frickenhausen, Germany 
96-well plates, U-bottom 650101 Greiner Bio-One, 
Frickenhausen, Germany 
96-well plates, U-bottom, 
non-binding 
650901 Greiner Bio-One, 
Frickenhausen, Germany 
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Amersham 
Hyperfilm™ELC 
28-9068-37 GE Healthcare Bio-
Sciences, Pittburgh, USA 
Cell culture flasks 
T75 
T175 
 
658175 
660175 
Greiner Bio-One, 
Frickenhausen, Germany 
Centrifugation tubes 
15ml 
50ml 
 
188261 
210261 
Greiner Bio-One, 
Frickenhausen, Germany 
Combitips advanced®, 
5.0 ml 
0030089456 Eppendorf, Hamburg, 
Germany 
Cryo-tubes, 1.5 ml 72379004 Sarstedt, Nümbrecht, 
Germany 
Nitrile gloves (Reha soft 
Nitrile) 
942206 Hartmann, Heidenheim, 
Germany 
PCR-plates (96-wells) Multiplate PCR plates / 
ML 9651 
Biorad, Hercules, 
California, USA 
Pasteur pipettes  WU, Mainz, Germany 
Pipette tips 
10 µl 
100 µl 
200 µl 
1250 µl 
 
692150 
692066 
692069 
790058 
Biozym, Hessisch 
Oldendorf, Germany 
Reaction tubes 
0.5 ml 
1.5 ml 
2.0 ml 
 
0030124537 
0030120086 
0030120094 
Eppendorf, Hamburg, 
Germany 
Serological pipettes 
5 ml 
10 ml 
25 ml 
 
357543 
357551 
357525 
Falcon, Franklin Lakes, 
NJ, USA 
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Syringes B-D Discardit II syringe 
(1100 x 2 ml) 
Becton, Dickinson and 
Company, Heidelberg, 
Germany 
Transfer membrane 
Immobilon™-p 
IPVH00010 Merck KGaA, Darmstadt, 
Germany 
Drain tubes 18 / 72379004 Becton, Dickinson and 
Company, Heidelberg, 
Germany 
 
2.1.5 Chemicals 
 
Table 6: Chemicals 
Name Material Number Manufacturer 
Acrylamide/bisacrylamide 
mixture, 30 % (Rotiphorese® Gel 
30) 
3029.1 Carl Roth GmbH & Co. 
KG, Karlsruhe, 
Germany 
Acryl Aqua Clean 0330111 WAK Chemie Medical 
GmbH, Steinbach, 
Germany 
Bio-Rad Protein Assay Dye 
Reagent concentrate 
500-0006 Bio-Rad Laboratories 
GmbH, Munich, 
Germany 
Bovine serum albumin (albumin 
fraction V, pH 7.0) 
A1391,0050 AppliChem GmbH, 
Darmstadt, Germany 
CellTiter 96 Aqueous One Solution 
Cell Proliferation Assay (MTS-
Assay) 
G3580 Promega, Fitchburg, 
Wiisconsin, USA 
Crystal violet T123.1 Carl Roth GmbH & Co. 
KG, Karlsruhe, 
Germany 
2 Materials and Methods 
33 
 
Descosept AF (surface 
desinfection) 
00-311-010 Dr. Schuhmacher, 
Malsfeld, Germany 
Dimethylsulfoxide (DMSO) C6295-50ml Sigma-Aldrich, St. 
Louis, Missouri, USA 
dNTP-Mix 20-2010 PEQLAB 
Biotechnologie GmbH, 
Erlangen, Germany 
ECL substrate (Thermo 
Scientific™ Pierce™ ECL Western 
Blotting Substrate) 
PI-32109 Thermo Scientific, 
Waltham, 
Massachusetts, USA 
EDTA 8040.3 Carl Roth GmbH & 
Co.KG, Karlsruhe, 
Germany 
Ethanol absolute 1.00983.2511 Merck, Darmstadt, 
Germany 
Fixable Viability Dye eFluor® 450 65-0863 eBioscience, San 
Diego, California, USA 
Formaldehyde 4235.2 Carl Roth GmbH & 
Co.KG, Karlsruhe, 
Germany 
Glycerol 1040921000 Merck, Darmstadt, 
Germany 
Glycine 0079 Carl Roth GmbH & 
Co.KG, Karlsruhe, 
Germany 
Halt Protease Inhibitor Cocktail 
EDTA free (100x) 
87785 Thermo Scientific, 
Waltham, 
Massachusetts, USA 
Methanol AnulaR Normapur 20847.307 VWR, Fontenay-Sous-
Bois, France 
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Powdered milk, blotting grade, low 
fat 
T145.2 Carl Roth GmbH & 
Co.KG, Karlsruhe, 
Germany 
Sodium dodecyl sulfate 20760 SERVA 
Electrophoresis GmbH, 
Heidelberg, Germany 
Sodium chloride 1.06404.1000 Merck, Darmstadt, 
Germany 
Sodium hydroxide 71690 Fluka, Buchs, 
Switzerland 
Tris ultrapure A1086 AppliChem GmbH, 
Darmstadt, Germany 
Triton X-100 T9284 Sigma-Alderich, St. 
Louis, Missouri, USA 
Trypan blue T8154 Sigma-Aldrich, St. 
Louis, Missouri, USA 
Tween® 20 9127.1 Carl Roth GmbH & 
Co.KG, Karlsruhe, 
Germany 
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2.1.6 Kits and enzymes 
 
Table 7: Kits and enzymes 
Name Material 
Number 
Manufacturer 
Random Primer Mix S 1330 S New England Biolabs, 
Ipswich, Massachusetts, USA 
RNeasy Mini-Kit 74104 Qiagen, Venlo, Netherlands 
RQ1 RNase-free DNase M6101 Promega, Fitchburg, 
Wisconsin, USA 
RT-PCR-Kit (10x RT-buffer, 
100 mM DTT, Reverse 
transcriptase) 
845-RT-5000 Analytik Jena, Jena, Germany 
SYBR Select Master Mix for 
CFX 
4472937 Life Technologies, Austin, 
Texas, USA 
 
2.1.7 Oligonucleotides 
 
Table 8: Oligonucleotides 
Name Sequence (5’→3’) Tm in °C 
Gli1 forward CCA ACT CCA CAG GCA TAC AGG AT 62.4 
Gli1 reverse CAC AGA TTC AGG CTC ACG CTT C 62.1 
Gli2 forward AAG TCA CTC AAG GAT TCC TGC 
TCA 
61.0 
Gli2 reverse GTT TTC CAG GAT GGA GCC ACT T 60.3 
Gli3 forward CGC GAC TGA ACC CCA TTC TAC 61.8 
Gli3 reverse GTG TTG TTG GAC TGT GTG CCA TT 60.6 
PTCH 1 forward CCC CTG TAG GAA GTG GAC ACT 
CTC 
66.1 
PTCH 1 reverse AAG GAA GAT CAC CAC TAC CTT 
GGC T 
63.0 
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SMO forward GCT ACT TCC TCA TCC GAG GAG 
TCA 
64.4 
SMO reverse GGC GCA GCA TGG TCT CTT 61.0 
TBP forward TGC ACA GGA GCC AAG AGT GAA 59.8 
TBP reverse CAC ATC ACA GCT CCC CAC CA 61.4 
The oligonucleotides were synthesised by Eurofins MWG Operon, Ebersberg, Germany. 
 
2.1.8 Buffers and Solutions 
Electrode buffer (10x)  250 mM Tris/HCL, pH 8.6; 2 M Glycine 
Running buffer   1:10 electrode buffer; 0.1 % (m/V) SDS 
Blotting buffer   1:10 electrode buffer; 20 % methanol 
Sample loading buffer (2x)  125 mM Tris/HCL, pH 6.8; 4 % (m/V) SDS 
   20 % (V/V) Glycerol      
   10 % (V/V) ß-mercaptoethanol    
   Bromphenol blue 
TBS-T     10 mM Tris/HCL, pH 7.5; 150 mM NaCl   
     0.1 % Tween 
Protein lysis buffer 40 mM Tris/HCl, pH 7.4; 300 mM NaCl; 2 mM 
EDTA; 20 % Glycerol; 2 % Triton X100 
FACS buffer    2 % FCS; 2 mM EDTA (Diluted in PBS) 
Crystal violet stock solution (10x) 1 % Crystal violet (diluted in 20 % ethanol) 
Crystal violet working solution 1:10 Crystal violet stock solution    
     (diluted in 20 % ethanol) 
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2.1.9 Antibodies 
 
Table 9: Antibodies 
Name Material Number Manufacturer 
ß-Tubulin (9FS) Rabbit 
mAb 
2128 Cell Signaling Technology, 
Danvers, Massachusetts, 
USA 
Cleaved Caspase 3 
(Asp175) (5A1E) Rabbit 
mAb 
9664 Cell Signaling Technology, 
Danvers, Massachusetts, 
USA 
Cleaved PARP (Asp214) 
(D64E10) XP® Rabbit 
mAb 
5625 Cell Signaling Technology, 
Danvers, Massachusetts, 
USA 
Gli1 Rabbit mAb 2553 Cell Signaling Technology, 
Danvers, Massachusetts, 
USA 
Gli2 (H-300) Rabbit pAb SC-28674 Santa Cruz, Dallas, Texas, 
USA 
Peroxidase AffiniPure 
Goat Anti-Rabbit IgG 
(H+L) 
111-035-003 Jacksson ImmunoResearch, 
West Grove, Pennsylvania, 
USA 
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Thermo Scientific PageRuler Prestained Protein Ladder (#26616) 
 
Figure 10: SDS-PAGE band profile of 
the PageRuler Prestained Protein 
Ladder. Images are from a 4 - 20 % 
Tris-glycine gel (SDS-PAGE) and 
subsequent transfer to membrane 
(Thermo Fisher Scientific, 2015). 
2.1.10 Software 
 
Table 10: Software 
Name Use Developers 
CFX-Manager™ Analysis of qTR-PCR 
data 
Biorad, Hercules, California, 
USA 
FACSDiva Acquisition of flow 
cytometry data 
Becton Dickinson, Franklin 
Lakes, New Jersey, USA 
FlowJo 4.6.2. Analysis of flow 
cytometry data 
Tree Star, Ashland, Oregon, 
USA 
Microsoft Office 
Paket 
Analysis of data, 
diagrams 
Microsoft Corporation, 
Redmond, USA 
Prism5 Calculation of IC50-
values 
GraphPad Software, La Jolla, 
California, USA 
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2.2 Methods 
2.2.1 Cell and molecular biological methods 
Cell culture 
Cells were cultured in T75 or T175 cell-culture flasks at 37 °C, 5 % CO2 and were 
passaged at 80 - 90 % confluency. For passaging, medium was removed, cells were 
washed with 5 ml PBS (10 ml for T175 flasks) and then enzymatically detached with         
2 ml (4 ml for T175 flasks) 1 x trypsin-EDTA (A673, RD-ES and SK-N-MC) or accutase 
(MSC-2014-7). The reaction was stopped after 5 min incubation at 37 °C, 5 % CO2 by 
adding medium containing fetal calf serum. 
Determination of cell number 
The cell suspension was centrifuged at 7 °C and 1500 rpm for 7 min. The supernatant was 
aspirated and the cell pellet diluted in 1 ml medium. 10 µl of a 1:10 diluted cell suspension 
were added to 90 µl trypan blue and pipetted between cover glass and Neubauer counting 
chamber. Living cells (not stained) in the four big squares were counted under the 
microscope and the number of cells per ml was calculated as follows: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 (
𝑐𝑒𝑙𝑙𝑠
𝑚𝑙
) = 𝑋 ÷ 4 × 104 × 10  Equation 1 
X = cells counted in all four big squares 
4 = quotient for four squares 
104 = chamber factor 
10 = 10 time dilution 
Freezing and thawing of cells 
For freezing of cells, cells were counted as described above and the cell suspension with 
1 x 106 cells was centrifuged at 7 °C and 1500 rpm for 7 min. The supernatant was 
aspirated and the cell pellet re-suspended in 1 ml of freezing-medium (10 % DMSO and 
90 % FCS). Cells in freezing-medium were transferred into a cryo-tube, which was kept 
at -20 °C for 1 h, then transferred into a -70 °C freezer overnight and kept in liquid 
nitrogen at -196 °C for long-time storage. 
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For thawing of cells, a cryo-tube was taken from liquid nitrogen and warmed up until the 
ice chunk had separated from edge of the tube. 5 ml culture medium were added to quickly 
inhibit the cytotoxic effect of DMSO and the suspension was transferred into a 15 ml 
centrifugation tube. Cells were centrifuged at 7 °C and 1500 rpm for 7 min, the 
supernatant was aspirated and the cell-pellet was re-suspended in 10 ml cell line specific 
medium. The cell suspension was transferred into a cell-culture flask (T75) which was 
filled up with the respective medium to 15 ml final volume. Medium was changed at the 
next day to remove cells that had not attached.  
Extraction of RNA from cell-lysate 
The innuPREP RNA Mini Kit from Analytik Jena was used for RNA extraction. 106 cells 
were harvested in a 1.5 ml Eppendorf tube and 350 µl of RLT buffer were added to the 
cell pellet. Subsequently, the cell pellet was re-suspended with help of an insulin syringe 
and either frozen at -20 °C or directly used for RNA extraction. 
Therefore, the lysate was transferred into a Spin Filter D and centrifuged at 10,000 g for 
2 min so that the lysate was completely filtrated into the 2.0 ml receiver tube. The filtrate 
was kept and mixed with 350 µl of 70 % ethanol. The sample was transferred into the 
Spin Filter R and centrifuged again at 10,000 g for 2 min. The receiver tube was replaced 
and 500 µl of washing solution HS were added to the Spin Filter which was centrifuged 
at 10,000 g for 1 min. This step was repeated with 700 µl of washing solution LS and the 
Spin Filter was centrifuged at 10,000 g once for 1 min and then for 3 min. Finally, the 
Spin Filter R was placed into a 1.5 ml Eppendorf tube and the sample was incubated with 
40 µl RNase-free water for 1 min at RT before centrifugation at 6,000 g for 1 min. The 
filtrate containing the RNA was either frozen at -20 °C or DNase digestion was carried 
out immediately. 
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DNAse digestion 
To eliminate any contamination with DNA, DNAse digestion was performed. Using the 
RQ1 RNase free DNase from Promega (Promega, Madison, Wisconsin, USA) each   
RNA-sample was treated as follows: 
 16 µl  RNA-sample 
 2 µl  10x DNase buffer 
 2 µl RQ1 DNase 
The mixture was incubated in a 1.5 ml Eppendorf tube at 37 °C for 30 min before adding 
2 µl stopping reagent for another 10 min at 65 °C.  
Following the DNase digestion, the RNA content and purity of each sample was measured 
using the NanoDrop (Thermo Scientific, Waltham, Massachusetts). Absorption of 1 µl of 
each sample was determined photometrically at 260 nm and 280 nm. 260 nm correspond 
to the maximum absorption of nucleic acids, whereas 280 nm correspond to that of 
proteins. 1 µl RNase-free water was used as a blank-value. Thus, a contamination of the 
RNA samples with DNA or proteins can be assumed when the quotient of 260 nm and 
280 nm is below 1.9. Pure RNA should have a value between 1.9 and 2.1. In addition the 
quotient of 260 nm and 230 nm, which should not come below 1.7 was determined to rule 
out any other aromatic contaminations. 
The RNA-concentration (C) was calculated as follows: 
𝑐(𝑅𝑁𝐴) = 𝐴260 × 𝐶    Equation 2 
A260  = Value of absorption at 260 nm 
𝐶  = nucleic acid specific coefficient for RNA of 0.04 µg/µl 
The samples were then either stored at -20 °C or reverse transcription to cDNA was 
performed. 
 
 
2 Materials and Methods 
42 
 
Reverse transcription 
For the transcription of RNA to complementary DNA (cDNA) a reverse transcriptase 
(RT) and short “random primer” were used. 1 µg of RNA were mixed with 2 µl of 60 µM 
“random primer” mix (New England Biolabs, Ipswich, Massachusetts, USA) in a 0.5 ml 
Eppendorf tube. To attain a final volume of 14.2 µl RNase-free-water was added, mixed 
slightly followed by incubation at 65 °C for 5 min. The samples were left at                   
room-temperature for another 10 min before addition of 5.8 µl of Master-Mix to each 
Eppendorf tube. 
 Master-Mix: 2 µl  10x RT-Buffer 
   0.64 µl  25 mM dNTP mix 
   2 µl  100 mM DTT 
   1 µl  RT-Enzyme 
 The entire Master-Mix was prepared for all samples. 
The samples were put into the PCR-machine and polymerase chain reaction (PCR) was 
started overnight: 
 10 min  25 °C 
 5 min  42 °C 
 60 min  55 °C 
 15 min  70 °C 
 Break  8 °C 
The cDNA was either kept at -20°C or used directly for a quantitative real-time PCR 
(qRT-PCR). 
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Quantitative Real-Time PCR 
To quantify the abundance of GLI1, GLI2, GLI3, PTCH1 and SMO mRNA, qRT-PCR 
was used. The qRT-PCR method detects the amount of cDNA after each amplification 
cycle by a fluorescent double-strand DNA intercalating dye (Rajeevan et al., 2001; 
Schmittgen et al., 2000). The reaction mixture consists of the SYBR Select Master Mix 
for CFX (Life Technologies, Austin, Texas, USA), both “forward” and “reverse” primers 
for the target genes GLI1, GLI2, GLI3, PTCH1, SMO or the control gene “TATA-Box 
Binding Protein” (TBP) (Eurofins MWG Operon, Ebersberg, Germany) and RNase free 
water. 
Reaction mixture: 5 µl SYBR Select Master Mix for CFX 
   1 µl forward Primer (10 µM) 
   1 µl reverse Primer (10 µM) 
   1 µl RNase free water 
To the 9 µl reaction mixture 1 µl cDNA (50 ng) or H20 as a negative control was pipetted. 
The 96 well plate was closed with foil and centrifuged at 7 °C and 1500 rpm for 7 min. 
All samples were prepared as duplicates and tested in four independent tests. The CFX96 
real-time System (Biorad, Hercules, USA) was used for the detection of the amplification 
products. Table 11 shows an overview of the qRT-PCR program. 
 
Table 11: qRT-PCR program. 
Temperature in °C Duration Number of cycles 
50 2 min 1 
95 2 min 1 
95 
60 
15 sec 
1 min 
45 
Melt curve from 75 °C to 95 °C: Increase of 0.2 °C in 1 sec 
25 2 min 1 
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During the PCR-reaction the wanted cDNA segment is amplified by binding of the 
specific oligonucleotides and the Taq-polymerase. Due to the intercalation of             
SYBR-Green in the new synthesized DNA, the fluorescence increases proportionally to 
the amount of DNA-product. The cycle threshold (Ct) marks the cycle where the specific 
fluorescence significantly increases above the background fluorescence. For the 
efficiency-corrected relative quantification (ΔΔCt) the “housekeeping” gene TBP was 
used as reference gene. The ratio (ΔCt) between the Ct-value of the gene of interest and 
the Ct-value of TBP was calculated: 
∆𝐶𝑡 = 𝐶𝑡(𝑔𝑒𝑛𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡) − 𝐶𝑡(𝑇𝐵𝑃)  Equation 3 
As the basal expression of genes in EWS cells in comparison to the basal expression in 
the control cells MSC-2014-7 was of interest, the ΔCt-values of both the EWS cell line 
and MSC-2014-7 were compared (ΔΔCt): 
∆∆𝐶𝑡 = ∆𝐶𝑡(𝐸𝑊𝑆 𝑐𝑒𝑙𝑙𝑠) − 𝐶𝑡(𝑀𝑆𝐶)  Equation 4 
The quantitative expression of the gene of interest could then be calculated as follows: 
𝐸 = 2−∆∆𝐶𝑡      Equation 5 
 
2.2.2 Cell Viability Test (MTS-Assay) 
To determine the effect of different substances on the viability of cells MTS assays were 
performed, where the reduction of the yellow 3-(4,5-dimethylthiazol2-yl)-5-(3-
carboxyphenyl)-2-(4-sulfophenyl)-2H-Tetrazoliumsalt (MTS) to a violet formazan is 
measured. This reaction is accomplished by the reduction equivalents NADPH and 
NADH and can be photometrically determined at 490 nm with the amount of measured 
colouring agent equal to the rate of glycolysis of the cells (Mosmann, 1983). 
For the MTS-assay cells were seeded into 96-well-plates using 0.5 x 104 cells/well (RD-
ES, SK-N-MC and MSC-2014-7) or 1.0 x 104 cells/well (A673) in 100 µl (A673, RD-ES 
and MSC-2014-7) or 250 µl (SK-N-MC) of medium. Cells were incubated at 37 °C,            
5 % CO2 for 24 h and then treated with different concentrations of the inhibitors by 
exchanging the medium. A control using the inhibitors solvent in accordance with the 
highest inhibitor concentration applied was also prepared. After 96 h incubation 15 µl 
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(A673 and RD-ES) or 20 µl (SK-N-MC) of MTS reagent (CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay, Promega, Fitchburg, Wisconsin, USA) were added to 
each well and plates were incubated for another 90 min at 37 °C and 5 % CO2. The 
absorbance was measured at 490 nm and a reference wavelength of 630 nm using an       
EL 800 reader (BioTek, Winooski, Vermont, USA). 
The negative control absorbance was set to 100 % and viability of treated cells calculated 
accordingly. Triplicates were prepared from each concentration and four independent 
experiments were performed. 
 
2.2.3 Clonogenic Assay 
To analyse the effect of the agents on the ability to proliferate and form colonies from 
single cells, a clonogenic assay was performed, which was first established with Hela 
cells in 1955 (Puck and Marcus, 1955). For this purpose very low densities of cells were 
evenly sown into 6-well-plates (A673 with 1000 cells/well; RD-ES and SK-N-MC with 
500 cells/well) by diluting the required cells in 2 ml medium and spreading them evenly 
onto the bottom of one well. Cells were allowed to attach for 24 h at 37 °C and 5 % CO2 
and then treated with different concentrations of inhibitors for another 72 h. The 
supernatant was aspirated and replaced with fresh medium without inhibitor every               
2 - 3 days for 9 - 15 days until colonies in negative controls were grown. Each                       
6-well plate included two negative controls treated with the inhibitors solvent. Colonies 
were stained with crystal violet. 
Stock solution: 1 % crystal violet in 20 % ethanol (v/v) 
Working solution: stock solution 1:10 in 20 % ethanol (v/v) 
For this the medium was aspirated and cells were washed with 1 ml/well PBS. After 
aspiration of PBS cells were incubated for 10 min at room temperature with 500 µl/well 
ice-cold methanol, remaining methanol was transferred into special waste and 500 µl of 
crystal violet working solution were added to each well. Plates were incubated for 30 min 
at room temperature on a horizontal shaker and then washed out with dH2O. 
Plates were dried upside down on cellulose paper and could be photographed the next 
day. 
2 Materials and Methods 
46 
 
2.2.4 Cell Death Assay (“Fluorescence Activated Cell Sorting”, FACS) 
Flow cytometry can assess several parameters of a cell population at the same time and 
evaluates large cell populations. The size of cells can be determined with the forward 
scatter (FSC) and the granularity with the side scatter (SSC). Furthermore, the expression 
of intracellular proteins and specific surface markers as well as the amount of DNA in the 
cells can be quantified. For the verification of cell death induction “Fixable viability dye 
Fluor - eFluor® 450” (eBioscience, San Diego, California, USA), a DNA-intercalating 
dye that only stains cells lacking an intact cell membrane was used. As the integrity of 
cell membranes is lost in dying cells eFluor® 450 uptake can serve as a marker (Fulwyler, 
1965; Julius et al., 1972). 
For the assay 2.5 x 105 MSC-2015-7 or A673, 1.5 x 105 RD-ES or 1 x 105 SK-N-MC cells 
were seeded in 2 ml corresponding medium into 6-well plates and incubated at 37 °C,      
5 % CO2 for 24 h. The medium was exchanged with 2 ml fresh medium containing single 
and combined concentrations of cytostatics and/or GLI1-inhibitors and plates were 
incubated for another 72 h at 37 °C, 5 % CO2. Each condition was assessed threefold 
including a negative control without inhibitor.  
For staining of the cells using “Fixable viability dye Fluor - eFluor® 450” medium was 
transferred into 2 ml Eppendorf tubes and the adherent cells were detached by incubating 
plates for 5 min at 37 °C, 5 % CO2 with 500 µl trypsin-EDTA (EWS cell lines) or accutase 
(MSC-2014-7). The detached cells were transferred into the respective Eppendorf tube 
containing the medium supernatant of the well and the tube was centrifuged for 5 min at 
5,000 g. The supernatant was removed carefully, cell pellets were re-suspended in 200 µl 
PBS and placed into the cavity of a round-bottom 96-well-plate. The plate was 
centrifuged for 5 min at 5,000 g. PBS was discarded and cells were washed once more 
with 200 µl PBS. The staining dye was prepared diluting “Fixable viability dye Fluor - 
eFluor® 450” 1:1000 in PBS. Cells were incubated for 30 min at 4 °C in the dark using 
100 µl of diluted dye per well. Following the incubation cells were centrifuged and 
washed once again with 200 µl PBS. After centrifugation cells were fixed with                 
100 µl/well 0.5 % formaldehyde at 4 °C in the dark. After 30 min of incubation the plate 
was centrifuged, cells washed with 200 µl PBS, centrifuged again and then pellets were 
re-suspended in 100 µl FACS-buffer. Plates could be stored at 4 °C for seven days until 
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analysis. Before measurement additional 100 µl FACS-buffer were added to each sample 
and cells were transferred into 5 ml FACS-vials. Kept on ice and protected from light, 
samples were analysed subsequently with an LSRII flow cytometer at 450 nm (BD 
Bioscience, Heidelberg, Germany). The results were calculated using the FlowJo 
Software (Tree Star Inc., Ashland, USA). 
 
2.2.5 Western blot 
To detect the abundance of specific proteins such as GLI1, GLI2 as well as the apoptotic 
cleavage of Poly (ADP-ribose) polymerase (PARP) and caspase 3 the method of the 
western blot was used. For this proteins were isolated and quantified, separated using gel 
electrophoresis, transferred onto a membrane and incubated with the corresponding 
antibodies. The method was first developed by Harry Towbin and shortly after refined by 
W. Neal Burnette (Burnette, 1981; Towbin et al., 1979). 
Preparation of protein samples 
1.5 x 105 cells were sown into 12-well plates containing 1 ml of medium per well and 
incubated at 37 °C and 5 % CO2. After 24 h cells were treated with different 
concentrations of inhibitors for 48 h. For a negative control cells were left in 1 ml of 
medium containing the inhibitor solvent for 2 days. 
The isolation of proteins was carried out on ice. Medium was transferred into a 2 ml 
Eppendorf tube, centrifuged at 5,000 rcf for 5 min and the cells were detached with        
500 µl of trypsin-EDTA (A673, RD-ES and SK-N-MC) or accutase (MSC-2014-7) in the 
meantime. 500 µl of the centrifuged supernatant were aspirated and the rest used to take 
up the detached cells. Once more, the samples were centrifuged at 5,000 rcf for 5 min and 
the supernatant was aspirated. To lyse the cells, 200 µl of lysis-buffer containing 1:100 
diluted proteinase-inhibitor were added to each Eppendorf tube. The lysates were 
sonificated 4 times for 20 s putting the samples on ice for 30 s between each sonification 
step. Samples were centrifuged at 13,800 rcf for 10 min and 200 µl of the supernatant 
transferred into a new Eppendorf tube. Proteins were kept at -20 °C. 
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Bradford Assay for quantification of protein concentration in samples 
Protein concentrations were quantified photometrically by adding Coomassie Brilliant 
Blue and performing a Bradford Assay. Coomassie Brilliant Blue is a triphenylmethane 
dye that appears red in its unbound form and blue in its protein bound form, which leads 
to a shift in the absorbance. Triphenylmethane can form complexes with cationic and non-
polar side chains of proteins under acidic conditions. For the statistically correct 
evaluation, triplets of each protein sample and samples of a BSA dilution series were 
used. Protein samples were thawed and diluted 1:100 in dH2O (3 µl protein sample +    
297 µl dH2O). For the dilution series a standard concentration stock with 1.41 mg/ml BSA 
was used. 
Dilution series: a) 100 µg/ml - 21.3 µl stock + 278.7 µl dH2O 
   b) 80 µg/ml - 17.0 µl stock + 283.0 µl dH2O 
   c) 60 µg/ml - 12.8 µl stock + 287.2 µl dH2O 
   d) 40 µg/ml - 8.5 µl stock + 292.5 µl dH2O 
   e) 20 µg/ml - 4.3 µl stock + 295.7 µl dH2O 
   f) 10 µg/ml - 2.13 µl stock + 297.87 µl dH2O 
   g) 5 µg/ml - 1.06 µl stock + 198.94 µl dH2O 
   h) blank - 300 µl dH2O 
Each 80 µl/well of the samples were pipetted into a 96-well-plate. 20 µl of staining 
reagent (Bio-Rad Protein Assay Dye Reagent Concentrate) were added to each well and 
mixed. The plate was incubated for 5 min and the absorbance was measured at 620 nm 
on the microplate reader (BioTek, Winooski, Vermont, USA) making sure no air bubbles 
were in the wells. 
SDS Page 
For separation of proteins based on their molecular weight and size the sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used. SDS denatures 
proteins and masks their original charge by a strong negative charge. Therefore, due to 
their molecular weight, smaller molecules migrate faster through the acrylamide matrix 
to the anode (positively charged electrode) finding themselves nearer to the bottom of the 
gel. By comparison to a marker containing proteins with specific known molecular 
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weights, the molecular weight of the separated proteins can be estimated (Raymond and 
Weintraub, 1959; Shapiro et al., 1967). 
For the SDS-PAGE, polyacrylamide gels consisting of a stacking gel (5 %) and a 
separating gel (10 %) were casted. Glass panels and combs from the Bio-Rad gel casting 
device were first cleaned with dH2O and 70 % ethanol. The station for the gels was set 
up, the glass panels put together and inserted into the holding device. 10 % separating gel 
and 5 % stacking gel were prepared in two 50 ml tubes. Table 12 shows the composition 
of the solutions sufficient for four gels. 
 
Table 12: Composition of SDS gels (sufficient for 4 gels). 
 
The separating gel was prepared and poured between glass panels leaving about 3 cm 
space at the top and covered with a 2 mm layer of isopropanol (approximately 300 µl per 
gel). After the separating gel had polymerised, isopropanol was removed and the gel was 
left for 5 min until all of the remaining isopropanol had vaporised. Then APS and TEMED 
were added to the stacking gel and the gel was poured on top of separating gel. Combs 
were inserted taking care that no air bubbles were enclosed and the gel was left until it 
had completely polymerised. Gels were used immediately or wrapped in damp paper and 
foil and stored at 4 °C for up to 3 days. 
Proteins were thawed in 1.5 ml Eppendorf tubes on ice, mixed with the same volume of 
sample buffer, incubated on the thermomixer at 95 °C for 5 min and stored on ice until 
loading on the gel. Gels were transferred into the electrophoresis chamber (Bio-Rad 
 Separating gel 10 % Stacking gel 5 % 
Destilled water (ddH2O) 15.8 ml 11 ml 
30 % Acrylamide 13.4 ml 2.6 ml 
1.5 M Tris/HCl pH 8.8 
(separating buffer) 
10 ml - 
1 M Tris/HCl pH 6.8 
(stacking buffer) 
- 2 ml 
20 % SDS 200 µl 80 µl 
10 % APS 400 µl 160 µl 
TEMED 16 µl 16 µl 
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Laboratories GmbH, Munich, Germany) and the chamber was filled with running buffer 
up to the markings. Combs were drawn carefully and the slots were rinsed with running 
buffer to remove any existing gel residual. 1 - 2 slots per gel were filled with each 5 µl of 
marker (Thermo Scientific PageRuler Prestained Protein Ladder (#26616)) and the 
proteins were pipetted carefully into the remaining slots making sure that no slot 
overflows (max 60 µl/slot). SDS-PAGE was run at 17 mA per gel (4 gels = 68 mA) until 
the blue running front nearly reached the end of gel (1.5 - 2 h). Gels were then 
immediately used for the western blot. 
Blotting 
For detection of apoptotic caspase 3 and PARP cleavage as well as GLI1 and GLI2, the 
western blot method was used. 
To transfer the proteins from the gel onto a PVDF membrane, sponges and whatman paper 
were soaked in blotting buffer, a PVDF membrane was put in 100 % methanol for 10 s 
before it was transferred into blotting buffer. The stacking gel had to be detached from 
separating gel and the blotting sandwich was assembled in a tub filled with blotting buffer 
to avoid any air getting enclosed. The blotting chamber was filled with blotting buffer up 
to marking and the blot was run at 20 V overnight for 16 - 18 h. 
Assembly of the blotting sandwich: 
- White side of support grid 
- 1 Sponge 
- 1 Whatman paper 
- PVDF membrane 
- Gel 
- 1 Whatman paper 
- 1 Sponge 
- Black side of support grid 
After proteins were blotted onto the PVDF membrane, the membranes were removed 
from the blot sandwich and stained with 1 % black ink (#17, Pelikan, Hannover, 
Germany) diluted in TBS-T (4 membranes need 30 ml) on horizontal shaker for 15 min. 
Ink was drained and membranes were washed with TBS-T for 5 min. For blocking, 5 % 
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milk powder in 20 ml TBS-T was prepared and membranes were incubated therein for  
30 min. For detection of the cleaved forms of caspase 3 (17 - 20 kDa) and PARP (89 kDa) 
as well as the loading control ß-tubulin (55 kDa) on the same membrane, membranes had 
to be cut into segments. For detection of GLI1 or GLI2, the entire membrane was 
incubated with the first antibody in 50 ml tubes at 4 °C overnight on a roller mixer. 
Dilution of first antibodies: 
anti-cleaved Caspase 3 (5A1E):  diluted 1:500 in 5 % milk powder in 20 ml 
TBS-T 
 ß-Tubulin (9F3) rabbit mAb:  diluted 1:2,000 in 5 % BSA in TBS-T 
 anti-cleaved PARP (DE64E10): diluted 1:500 in 5 % BSA in TBS-T 
 GLI1 Rabbit mAb:   diluted 1:10,000 in 5 % BSA in TBS-T 
 GLI2 (H-300):   diluted 1:200 in 5 % BSA in TBS-T 
After the first antibody incubation membranes were washed 3-times with TBS-T for each 
15 min. The membranes were incubated for 2 h with the secondary, horseradish 
peroxidase conjugated antibody diluted 1:10,000 in 40 ml 5 % milk powder in TBS-T. 
After three washing steps using TBS-T for each 15 min, membranes were covered with  
4 ml of “enhanced chemiluminescent substrate” (ECL-solution) for two minutes. The 
remaining liquid was discarded and membranes were wrapped in plastic foil. For 
development, the wrapped membranes were placed into a film cassette and a film was 
exposed to the membrane for a period of time depending on the detected protein (Caspase 
3 and PARP: 45 min; ß-tubulin: 2 - 5 min; Gli1: 25 - 30 min; Gli2: 10 sec). The film was 
developed with an automatic developing machine (Agfa-Gevaert N. V., Mortsel, 
Belgium). 
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2.2.6 3D spheroid cultures 
To analyse the effect agents have on cells growing in a 3D culture, substances were tested 
on cells grown as spheroids as described in a paper by Vinci et al. (Vinci et al., 2012). 
Only the cell lines A673 and SK-N-MC were able to form spheroids, therefore, RD-ES 
had to be excluded from this experiment. 
Cells were sown out in non-adherent round-bottom 96-well-plates (A673:                            
0.5 x 104 cells/well in 150 µl medium; SK-N-MC: 0.25 x 104 cells/well in 200 µl medium) 
and the plate was centrifuged for 7 min at 1500 rpm. As SK-N-MCs did not yet stick 
together, the plate was centrifuged for another 7 min at 1500 rpm the next day. After          
4 days spheroids were photographed at the microscope (Leica, Wetzlar, Germany)        
(day 0) and thereafter treated with different concentrations of inhibitors in a final volume 
of 250 µl for another 4 days until a second micrograph was taken (day 4). For each 
condition four spheroids were analysed and medium with solvent was added to the                
4 negative controls. 
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3 Results 
3.1 Identification of Hedgehog pathway component expression profiles 
in Ewing sarcoma cell lines 
The EWS-FLI1 fusion protein typical for Ewing sarcoma is known to modulate the 
expression of genes involved in multiple signalling pathways including the Hh pathway 
(Taylor et al., 2011). Previous studies have identified the GLI1 protein as a direct 
transcriptional target of EWS-FLI1 (Beauchamp et al., 2009). As GLI1 is involved in 
tumourigenesis and can be targeted by different inhibitors, the expression of GLI1 was of 
special interest in this work. Basal expression of both activating transcription factors 
GLI1 and GLI2 was analysed at mRNA and protein level. Moreover, the mRNA 
expression of additional pathway components like GLI3, SMO and PTCH was examined. 
Finally, the influence of the GLI inhibitor ATO on levels of GLI1 protein in EWS cell 
lines was investigated. 
3.1.1 Quantification of Hh pathway mRNA expression in A673, RD-ES and        
SK-N-MC cells in comparison to MSC 
As a basis of this work, the expression of GLI1, GLI2, GLI3, SMO and PTCH1 mRNA 
in the three EWS cell lines A673, RD-ES and SK-N-MC in comparison to healthy MSC 
was analysed by qRT-PCR. 
In figure 11 the results of the mRNA expression analysis are presented. The mRNA 
expression in MSC-2014-7 was set to 100 %. The results show an overexpression of 
GLI1-mRNA only in the cell lines A673 (803 ± 40 %) and RD-ES (193 ± 44 %).             
SK-N-MC cells expressed lower levels of GLI1 (35 ± 1 %) than MSC. However, only in 
A673 cells GLI1-mRNA abundance was significantly higher than in MSC. An 
overexpression of GLI2-mRNA could only be proved in A673 cells (185 ± 41 %). Both 
RD-ES and SK-N-MC cells showed GLI2-mRNA expression levels similar to MSC. 
GLI3 was slightly overexpressed in A673 cells (155 ± 44 %) but underexpressed in both 
RD-ES (13 ± 6 %) and SK-N-MC (26 ± 2 %) cells. In contrary to A673 and SK-N-MC, 
the RD-ES cell line was the only cell line showing reduced SMO-mRNA compared to 
MSC. Interestingly, all three EWS cell lines presented an overexpression of              
PTCH1-mRNA (A673: 314 ± 35 %; RD-ES: 131 ± 11 %; SK-N-MC: 159 ± 24 %) which 
was especially significant in A673 cells. 
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Figure 11: Relative expression of Hedgehog pathway genes in EWS cell lines A673, RD-ES and             
SK-N-MC in comparison to MSC-2014-7. Each 1 x 106 cells of A673, RD-ES, SK-N-MC and MSC were 
lysed, the mRNA cleaned and transcribed into cDNA. 50 ng of cDNA were analysed by qRT-PCR. Ct-values 
of the genes GLI1, GLI2, GLI3, SMO and PTCH1 were determined. For calculation of the ΔCt-values of 
all analysed genes the expression of the reference gene TBP was also determined. The ΔΔCt-values were 
determined by comparison of gene expression in control cells MSC-2014-7 with gene expression in EWS 
cell lines. Gene expression is given in percent, expression in MSC-2014-7 was set to 100 %. Mean values 
were plotted from four independent replicates. Standard deviations are represented by black error bars. 
Data presented in this figure was also published (Boehme et al., 2016 (1)). 
3.1.2 GLI1 and GLI2 protein expression in A673, RD-ES and SK-N-MC in 
comparison to MSC 
To determine the GLI1 and GLI2 protein levels of A673, RD-ES and SK-N-MC in 
comparison to MSC western blot analysis was performed. Figure 12 shows the 100 kDa 
GLI1 isoform and also higher molecular weight bands in all three EWS cell lines. 
Moreover, MSC also present a slight band at 100 kDa with a very faint ß-tubulin band 
compared to the EWS cell lines. However, having set the GLI1 protein levels in MSC to 
100 %, the quantified data suggests that all three EWS cell lines hold comparable levels 
of GLI1 protein, which are lower than in MSC (A673: 63 %; RD-ES: 57 % and                
SK-N-MC: 67 %). Furthermore, GLI1 protein in A673 cells is not higher expressed than 
in RD-ES and SK-N-MC which would have been expected based on GLI1-mRNA levels 
of A673. Interestingly, smaller bands are found in all cell lines, including a very dominant 
band running at 45 - 55 kDa in the MSC-2014-7 lane. 
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Figure 12: Expression of GLI1 protein in the EWS cell lines A673, RD-ES and SK-N-MC as well as 
MSC-2014-7. 1.5 x 104 cells/well of A673, RD-ES, SK-N-MC or MSC-2014-7 were sown into a 12-well 
plate. After 72h proteins were isolated and their concentration was measured with Bradford assay. For the 
western blot protein samples were loaded as follows: lane 1: MSC-2014-7; lane 2: A673; lane 3: RD-ES 
and lane 4: SK-N-MC. Proteins were separated by SDS-PAGE and blotted onto a PVDF membrane. 
Membranes were incubated with the primary antibodies GLI1 rabbit Ab or tubulin rabbit mAb overnight. 
A horseradish peroxidase-conjugated anti-rabbit pAb was used as secondary antibody. ECL substrate was 
added to the membrane and chemiluminescence signals were recorded on a film. ImageJ was utilised for 
western blot quantification. Data presented in this figure was also published (Boehme et al., 2016 (1)). 
Figure 13 shows the expression of the full length and repressor form of GLI2 protein. In 
MSC-2014-7 with the GLI2 antibody significant running at 80 kDa and 170 kDa were 
detected. In the EWS cell lines the upper band had a size of about 130 kDa, whereas the 
80 kDa band was detected as well. As ß-tubulin expression varied strongly, the expression 
of both full length and repressor form of GLI2 was set in relation to the equivalent              
ß-tubulin expression. Therefore, the quantified data showed decreased expression of both 
GLI2 forms in all EWS cell lines, compared to MSC whose GLI2 levels were set to        
100 %. GLI2 full length expression of the EWS cell lines in comparison to MSC was 
slightly higher (GLI2 full length in A673: 13 %; RD-ES: 17 % and SK-N-MC: 27 %) 
than the repressor form (GLI2 repressor form in A673: 6 %; RD-ES: 12 % and                  
SK-N-MC: 18 %). 
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Figure 13: Expression of GLI2 protein in the EWS cell lines A673, RD-ES and SK-N-MC as well as 
MSC-2014-7. 1.5 x 104 cells/well of A673, RD-ES, SK-N-MC or MSC-2014-7 were sown into a 12-well 
plate. After 72h proteins were isolated and their concentration was measured with Bradford assay. For the 
western blot protein samples were loaded as follows: lane 1: MSC-2014-7; lane 2: A673; lane 3: RD-ES 
and lane 4: SK-N-MC. Proteins were separated by SDS-PAGE and blotted onto a PVDF membrane. 
Membranes were incubated with the primary antibodies GLI2 rabbit pAb or tubulin rabbit mAb overnight. 
A horseradish peroxidase-conjugated anti-rabbit pAb was used as secondary antibody. ECL substrate was 
added to the membrane and chemiluminescence signals were recorded on a film. ImageJ was utilised for 
western blot quantification. Data presented in this figure was also published (Boehme et al., 2016 (1)). 
 
3.2 Effect of GANT61, ATO, etoposide and doxorubicin on the viability 
of Ewing sarcoma cell lines 
Inhibition of the Hh pathway in different types of cancer has proven efficiency in several 
studies (Agyeman et al., 2014; Hu et al., 2009; Rudin, 2012). As described in chapter 
1.3.3, EWS-FLI1 interacts with the Hh pathway downstream of SMO and PTCH1. 
Therefore, the effect of the GLI1 inhibitors GANT61 and ATO as well as the cytostatics 
etoposide and doxorubicin, already used in EWS therapy (chapter 1.5), on the viability of 
EWS cells in comparison to healthy MSC was analysed by MTS assay. 
 
 
3 Results 
57 
 
3.2.1 Effect of single substance treatment on the viability of A673, RD-ES,          
SK-N-MC and MSC 
GANT61 
Figure 14 shows that the EWS cell line A673 has the highest sensitivity to GANT61. A 
significant drop in viability was already achieved using 15 µM GANT61 (35 ± 7 %) 
whereas 50 µM reduced viability to 14 ± 2 % of the mock treated control. Both RD-ES 
and SK-N-MC cells showed no significant decrease in viability using concentrations up 
to 25 µM GANT61 (RD-ES: 106 ± 4 % and SK-N-MC: 100 ± 5 %). 50 µM GANT61 
reduced the viability to 49 ± 12 % in RD-ES 73 ± 10 % in SK-N-MC. Unfortunately, the 
healthy control cells MSC-2014-7 showed a similar sensitivity as A673 cells. The 
viability of MSC started to decrease at a dose of 10 µM GANT61 (79 ± 4 %) and reached 
a plateau at 25 µM (7 ± 0 %), being the lowest viability attained in all cells examined. 
 
Figure 14: Effect of GANT61 on the viability of the EWS cell lines A673, RD-ES and SK-N-MC in 
comparison to MSC. 0.5 x 104 cells/well RD-ES, SK-N-MC and MSC-2014-7 or 1 x 104 cells/well A673 
were sown into 96-well plates. After 24 h cells were treated with different concentrations of GANT61 or 
the inhibitors solvent in case of the negative controls for 96 h. For analysis cells were incubated with MTS 
reagent and absorbance was measured at 490 nm. Negative controls were set to 100 % viability and the 
relative viability was calculated. Mean values were plotted from four independent experiments. Standard 
deviations are represented by black error bars. 
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Arsenic trioxide 
Figure 15 shows that A673 cells also exhibited the highest ATO sensitivity of all EWS 
cell lines, with 0.5 µM ATO reducing viability to 43 ± 5 % and reaching even lower 
values at 2 µM ATO (24 ± 3 %) and 5 µM ATO (23 ± 2 %). RD-ES and SK-N-MC were 
less sensitive, retaining 31 ± 4 % (RD-ES), respectively 47 ± 4 % (SK-N-MC) viable cells 
at 5 µM ATO. Moreover, viability of RD-ES did not drop before 2 µM (53 ± 7 %) and 
93 ± 10 % of SK-N-MC cells were viable at 3 µM ATO. Interestingly, the MSC showed 
an increase of viability upon treatment with ATO concentrations up to 5 µM                     
(130 ± 14 %), whereas 10 µM reduced viability to 82 ± 6 %. 
 
Figure 15: Effect of ATO on the viability of the EWS cell lines A673, RD-ES and SK-N-MC in 
comparison to MSC. 0.5 x 104 cells/well RD-ES, SK-N-MC and MSC-2014-7 or 1 x 104 cells/well A673 
were sown into 96-well plates. After 24 h cells were treated with different concentrations of ATO or the 
inhibitors solvent in case of the negative controls for 96 h. For analysis cells were incubated with MTS 
reagent and absorbance was measured at 490 nm. Negative controls were set to 100 % viability and the 
relative viability was calculated. Mean values were plotted from four independent experiments. Standard 
deviations are represented by black error bars. 
Etoposide 
Figure 16 shows that all three EWS cell-lines have a similar sensitivity to etoposide with 
a significantly decreased viability after addition of 1 µM etoposide (A673: 63 ± 5 %;    
RD-ES:  58 ± 4 % and SK-N-MC: 67 ± 13 %). Moreover, 5 µM etoposide reduced the 
viability to 34 ± 3 % in A673 cells, 39 ± 1 % in SK-N-MC cells or even 18 ± 3 % in      
RD-ES cells. The control cells MSC-2014-7 seemed to be completely resistant to all 
etoposide concentrations applied with viability not falling below 96 ± 9 % at 10 µM 
etoposide, which reduced the viability of A673 to 19 ± 1 %, RD-ES to 13 ± 2 % and      
SK-N-MC to 30 ± 2 %, respectively. 
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Figure 16: Effect of etoposide on the viability of the EWS cell lines A673, RD-ES and SK-N-MC in 
comparison to MSC. 0.5 x 104 cells/well RD-ES, SK-N-MC and MSC-2014-7 or 1 x 104 cells/well A673 
were sown into 96-well plates. After 24 h cells were treated with different concentrations of etoposide or 
the inhibitors solvent in case of the negative controls for 96 h. For analysis cells were incubated with MTS 
reagent and absorbance was measured at 490 nm. Negative controls were set to 100 % viability and the 
relative viability was calculated. Mean values were plotted from four independent experiments. Standard 
deviations are represented by black error bars. 
Doxorubicin 
Figure 17 shows that the lowest viability obtained by incubation with 100 nM 
doxorubicin was 41 ± 1 % in A673 cells, 49 ± 2 % in RD-ES cells and 43 ± 4 % in          
SK-N-MC cells, while viability of MSC did not drop under 61 ± 4 % using the same 
concentration. Furthermore, applying 50 nM doxorubicin 81 ± 3 % of MSC were viable 
compared to 39 ± 3 % (A673), 61 ± 3 % (RD-ES) and 57 ± 3 % (SK-N-MC) in the EWS 
cell lines. 
 
Figure 17: Effect of doxorubicin on the viability of the EWS cell lines A673, RD-ES and SK-N-MC in 
comparison to MSC. 0.5 x 104 cells/well RD-ES, SK-N-MC and MSC-2014-7 or 1 x 104 cells/well A673 
were sown into 96-well plates. After 24 h cells were treated with different concentrations of doxorubicin or 
the inhibitors solvent in case of the negative controls for 96 h. For analysis cells were incubated with MTS 
reagent and absorbance was measured at 490 nm. Negative controls were set to 100 % viability and the 
relative viability was calculated. Mean values were plotted from four independent experiments. Standard 
deviations are represented by black error bars. 
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IC50 values 
For the administration in patients a significantly more distinct effect of the substances on 
cancer cells compared to normal, healthy cells is required. As shown in Table 13 upon 
treatment with ATO, etoposide and doxorubicin the EWS cell lines A673, RD-ES and 
SK-N-MC were significantly more sensitive compared to MSC, indicating high 
selectivity of these drugs. Only GANT61 reduced the viability of the control cells       
MSC-2014-7 sufficiently to determine an IC50 value. Moreover, MSC exhibited a lower 
GANT61 IC50 value than the EWS cell lines RD-ES and SK-N-MC. 
 
Table 13: IC50 values of the EWS cell lines A673, RD-ES and SK-N-MC compared to the control cells 
MSC-2014-7 after treatment with ATO, GANT61, etoposide or doxorubicin. MTS-Assays were performed 
four days after treatment with ATO, GANT61, etoposide or doxorubicin in the three EWS cell lines and 
MSC-2014-7 in quadruplicate. Mock treated control was set to 100 % viability. IC50 values were determined 
by non-linear regression of the MTS results using GraphPad Prism. Data presented in this table was also 
published (Boehme et al., 2016 (1)). 
Cell line IC50 – 
ATO 
IC50 – 
GANT61 
IC50 – 
etoposide 
IC50 – 
doxorubicin 
A673 0.23 µM 12.01 µM 0.88 µM 27.18 nM 
RD-ES 1.91 µM 35.37 µM 1.06 µM 115 nM 
SK-N-MC 4.42 µM 59.56 µM 1.11 µM 75.15 nM 
MSC-
2014-7 
10 µM ATO 
82.4 % viable 
16.05 µM 35 µM etoposide 
85.6 % viable 
150 nM doxorubicin 
58.6 % viable 
 
Summary 
Viability of the EWS cell lines could be reduced by all four inhibitors applied. MSC 
seemed to be largely resistant to the ATO and etoposide doses applied. Although 
treatment with 150 nM doxorubicin reduced the viability of MSC-2014-7 down to 60 %, 
all EWS cell lines appeared to be more sensitive. Only GANT61 was not selective 
between MSC and the EWS cell lines tested. Therefore, it was excluded from combination 
experiments. 
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3.2.3 Effect of inhibitor combinations on the viability A673, RD-ES, SK-N-MC and 
MSC 
Etoposide and Arsenic trioxide 
Figure 18 demonstrates the effect of combined etoposide and ATO treatment of the EWS 
cell lines in comparison to MSC. In A673 cells (Figure 18A) a clear dependency of the 
viability on the etoposide dose is visible, whereas an increase of the ATO dose was less 
critical for the combined effect. Using 0.5 µM etoposide viability was reduced to               
87 ± 9 %. Increasing ATO concentrations from 0.1 µM to 0.3 µM reduced the viability 
from 104 ± 13 % to 51 ± 5 %. However, applying combinations of ATO and etoposide 
viability stagnated between 67 % and 70 %, which was, in case of treatment with 0.2 µM 
and 0.3 µM ATO, still higher compared to single treatment with ATO. This effect could 
be repeated using 0.75 µM etoposide (viability after single treatment: 72 ± 7 %) combined 
with 0.1 µM to 0.3 µM ATO, where combined treatment led to a viability of 54 ± 7 % to 
52 ± 5 %. Only using an etoposide concentration of 1 µM (viability after single treatment: 
63 ± 5 %), the viability of cells treated with the drug combinations was clearly reduced 
below that of ATO treated cells to about 40 % for the combination with 0.1 µM and          
0.2 µM ATO, respectively. This combined effect was intensified applying 0.3 µM ATO 
and 1 µM etoposide (viability of 30 ± 2 %).  
In RD-ES cells viability after combined treatment was more dependent on the increase of 
the ATO dose (Figure 18B). Treatment with 0.5 µM etoposide (viability after single 
treatment: 77 ± 3 %) and 1 µM ATO (viability after single treatment: 83 ± 15 %) already 
resulted in a very significant drop of viability upon combination (47 ± 8 %). Viability was 
reduced further to 32 ± 4 % in cells treated with 0.5 µM etoposide and 1.5 µM ATO 
(viability after single treatment with 1.5 µM ATO: 72 ± 5 %) or even to 25 ± 2 % after 
application of 0.5 µM etoposide and 2 µM ATO (viability after single treatment with         
2 µM ATO: 53 ± 7 %). Combinations using increasing concentrations of 0.75 µM 
etoposide (viability after single treatment: 69 ± 3 %) or 1 µM etoposide (viability after 
single treatment: 58 ± 4 %) led to no further reduction of the viability of RD-ES cells 
compared to using 0.5 µM etoposide.  
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Figure 18: Effect of combined etoposide and ATO treatment on the viability of the EWS cell lines         
A673, RD-ES and SK-N-MC. A: 1 x 104 cells/well A673, B: 0.5 x 104 cells/well RD-ES and                                 
C: 0.5 x 104 cells/well SK-N-MC were sown into 96-well plates. After 24 h cells were treated with single 
concentrations and combinations of etoposide (Eto) and ATO as well as the inhibitors solvents in case of 
the negative controls for 96 h. For analysis cells were incubated with MTS-reagent and absorbance was 
measured at 490 nm. Negative controls were set to 100 % viability and the relative viability was calculated. 
Mean values were plotted from four independent experiments. Standard deviations are represented by black 
error bars. Data presented in this figure was also published (Boehme et al., 2016 (1)). 
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Figure 19: Effect of combined etoposide and ATO treatment on the viability of MSC-2014-7 control cells. 
0.5 x 104 cells/well MSC-2014-7 were sown into 96-well plates. After 24 h cells were treated with single 
concentrations and two combinations of etoposide (Eto) and ATO as well as the inhibitors solvents in case 
of the negative controls for 96 h. For analysis cells were incubated with MTS-reagent and absorbance was 
measured at 490 nm. Negative controls were set to 100 % viability and the relative viability was calculated. 
Mean values were plotted from four independent experiments. Standard deviations are represented by black 
error bars. Data presented in this figure was also published (Boehme et al., 2016 (1)). 
SK-N-MC cells (Figure 18C) were least sensitive to treatment using etoposide or ATO. 
Upon combination of the highest drug doses applied, 1 µM etoposide and 3 µM ATO,    
49 ± 2 % of cells were still viable, whereas single doses of etoposide or ATO reduced 
viability to 64 ± 4 % or 77 ± 4 %, respectively. All other combined treatments were less 
efficient: 57 ± 2 % (0.5 µM etoposide / 3 µM ATO) and 56 ± 2 % (0.75 µM             
etoposide / 3 µM ATO) with decreased etoposide or ATO doses having even reduced 
impact on viability upon single treatment. 
Figure 19 shows the reaction of MSC-2014-7 cells to combined treatment using the 
highest doses of 1 µM etoposide and 2 or 3 µM ATO applied to the EWS cell lines A673, 
RD-ES and SK-N-MC. Viability only dropped to 92 ± 4 % upon application of 1 µM 
etoposide and 92 ± 4 % upon treatment with the combination of 1 µM etoposide with         
3 µM ATO. Interestingly, single application of 3 µM ATO increased viability of MSC to 
130 ± 13 %. 
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Doxorubicin and Arsenic trioxide 
Figure 20A shows a strong dependence of A673 cell viability on the ATO doses applied. 
Combined treatment with 5 nM doxorubicin (viability after single treatment: 97 ± 9 %) 
and 0.2 µM ATO (viability after single treatment: 72 ± 4 %) already resulted in a very 
significant drop of viability to 47 ± 8 %. Viability was reduced further to 28 ± 3 % in cells 
treated with 5 nM doxorubicin and 0.3 µM of ATO (viability after single treatment:            
51 ± 2 %). Increasing the concentrations of doxorubicin to 10 nM (viability after single 
treatment: 96 ± 9 %) and 30 nM (viability after single treatment: 85 ± 9 %) led to no 
further combined reduction of the viability of A673 cells (27 ± 1 % for 10 nM doxorubicin 
/ 0.3 µM ATO; 27 ± 1 % for 30 nM doxorubicin / 0.3 µM ATO). Using a low dose of    
0.1 µM ATO (viability after single treatment: 99 ± 8 %) in combination with 5 nM,           
10 nM or 30 nM doxorubicin did not result in a significant loss of viable cells in 
comparison to doxorubicin single treatment except for the combination of 10 nM 
doxorubicin with 0.1 µM ATO where viability decreased to 73 ± 4 %. 
In RD-ES cells (Figure 20B) both increasing ATO and doxorubicin doses affected the 
combined outcome. Treatment of cells with 5 nM doxorubicin and increasing ATO 
concentrations only resulted in a significant intensification of viability loss when the 
highest ATO concentration of 2 µM had been used (5 nM doxorubicin: viability                  
99 ± 5 %; 2 µM ATO: viability 53 ± 7 %; combination: viability 30 ± 2 %). When 
doubling the dose of doxorubicin to 10 nM (viability after single treatment: 80 ± 6 %) a 
significant effect was achieved in combination with 1.5 µM ATO (viability after single 
treatment: 72 ± 5 %; combined: viability 41 ± 6 %), whereas a combination with 2 µM 
ATO led to an even lower viability (10 nM doxorubicin / 2 µM ATO: 27 ± 1 %) of          
RD-ES cells. The smallest number of viable cells was obtained with 30 nM doxorubicin 
(viability after single treatment: 59 ± 2 %) combined with 1.5 µM ATO (26 ± 2 %) or 
combined with 2 µM ATO (21 ± 1 %).  
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Quite contrary to the cell lines A673 or RD-ES, combination treatment of SK-N-MC cells 
(Figure 20C) was only favourable using 30 nM doxorubicin (viability after single 
treatment: 56 ± 1 %) in combination with 1.5 µM ATO (viability after single treatment: 
95 ± 5 %) reducing viability to 45 ± 3 %, which was even slightly improved by increasing 
ATO doses to 2 µM (combination: viability 43 ± 3 %) or 3 µM (combination: viability 
36 ± 3 %). Whereas upon treatment with 3 µM ATO alone 78 ± 13 % of cells were still 
viable.  
The highest concentrations of 30 nM doxorubicin and 2 µM or 3 µM ATO applied in 
EWS were not sufficient to reduce viability in MSC-2014-7 cells below 87 ± 3 % obtained 
with 30 nM doxorubicin single treatment as shown in Figure 21. 
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Figure 20: Effect of combined doxorubicin and ATO treatment on the viability of the EWS cell lines 
A673, RD-ES and SK-N-MC. A: 1 x 104 cells/well A673, B: 0.5 x 104 cells/well RD-ES and C: 0.5 x 104 
cells/well SK-N-MC were sown into 96-well plates. After 24 h cells were treated with single concentrations 
and combinations of doxorubicin (Doxo) and ATO as well as the inhibitors solvents in case of the negative 
controls for 96 h. For analysis cells were incubated with MTS-reagent and absorbance was measured at 
490 nm. Negative controls were set to 100 % viability and the relative viability was calculated. Mean values 
were plotted from four independent experiments. Standard deviations are represented by black error bars. 
Data presented in this figure was also published (Boehme et al., 2016 (1)). 
 
Figure 21: Effect of combined doxorubicin and ATO treatment on the viability of MSC-2014-7 control 
cells. 0.5 x 104 cells/well MSC-2014-7 were sown into 96-well plates. After 24 h cells were treated with 
single concentrations and two combinations of doxorubicin (Doxo) and ATO as well as the inhibitors 
solvents in case of the negative controls for 96 h. For analysis cells were incubated with MTS-reagent and 
absorbance was measured at 490 nm. Negative controls were set to 100 % viability and the relative viability 
was calculated. Mean values were plotted from four independent experiments. Standard deviations are 
represented by black error bars. Data presented in this figure was also published (Boehme et al., 2016 (1)). 
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Etoposide, doxorubicin and Arsenic trioxide 
For further evaluation of the effect of cytostatics and ATO on the viability of EWS cell 
lines, cells were treated with two triple combinations of etoposide, doxorubicin and ATO. 
Concentrations for triple treatment were selected on the basis of the previous viability 
assay results. 
In A673 cells (Figure 22A) a combination of 1 µM etoposide (viability after single 
treatment: 63 ± 5 %), 5 nM doxorubicin (viability after single treatment: 109 ± 5 %) and 
0.1 µM ATO (viability after single treatment: 99 ± 5 %) was sufficient to drastically 
reduce viability to 33 ± 1 %. This was also an improvement compared to the respective 
double applications (0.1 µM ATO / 1 µM etoposide: 40 ± 5 % and 0.1 µM ATO / 5 nM 
doxorubicin: 90 ± 9 %). Additional loss of viability was not obtained using 0.3 µM ATO 
together with 5 nM doxorubicin and 1 µM etoposide (37 ± 1 %). Indeed, viability was 
higher compared to both double treatments (0.3 µM ATO / 5 nM doxorubicin: 28 ± 3 % 
and 0.3 µM ATO / 1 µM etoposide: 30 ± 2 %). 
As already described, RD-ES cells (Figure 22B) presented a less pronounced drop in 
viable cells when applying 0.5 µM etoposide (77 ± 3 %), 5 nM doxorubicin (99 ± 5 %) 
or 1 µM ATO (83 ± 15 %) as single dose. The triple combination led to 51 ± 2 % viable 
cells, which was equal compared to the double combination of 0.5 µM etoposide and         
1 µM ATO (47 ± 8 %). However, with the dose of ATO doubled (2 µM ATO: 53 ± 7 %) 
viability of the triple approach reached a level as low as 20 ± 1 %, which was superior 
compared to both double combinations (0.5 µM etoposide / 2 µM ATO: 25 ± 2 % and     
5 nM doxorubicin / 2 µM ATO: 30 ± 2 %). 
SK-N-MC cells (Figure 22C) were requiring higher doses of doxorubicin and ATO. A 
viability of 39 ± 2 % could be obtained with combined treatment of cells with 0.5 µM 
etoposide (viability after single treatment: 77 ± 6 %), 30 nM doxorubicin (viability after 
single treatment: 66 ± 9 %) and 3 µM ATO (viability after single treatment: 77 ± 4 %). 
However, using the double combination of 30 nM doxorubicin and 3 µM ATO                  
(36 ± 3 %) was more efficient. In SK-N-MC the applied etoposide dose was increased to 
1 µM (viability after single treatment: 64 ± 4 %), which showed no further impact on 
viability after triple application (1 µM etoposide / 30 nM doxorubicin / 3 µM ATO:           
37 ± 1 %). Indeed, both double treatments obtained similar results (3 µM ATO / 1 µM 
etoposide: 49 ± 2 % and 3 µM ATO / 30 nM doxorubicin: 36 ± 3 %). 
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For control (Figure 23) MSC-2014-7 cells were treated with the highest drug doses 
applied in combination (1 µM etoposide, 30 nM doxorubicin and 3 µM ATO) in the three 
EWS cell lines. Viability was not reduced below 96 ± 5 % (single application of 30 nM 
doxorubicin), which shows that even a triple combination had barely any effect on the 
viability of the control cells. 
 
 
Figure 22: Effect of combined etoposide, doxorubicin and ATO treatment on the viability of the EWS cell 
lines A673, RD-ES and SK-N-MC. A: 1 x 104 cells/well A673, B: 0.5 x 104 cells/well RD-ES and                                
C: 0.5 x 104 cells/well SK-N-MC were sown into 96-well plates. After 24 h cells were treated with two triple 
combinations, the single concentrations and the double combinations of etoposide (Eto) and ATO as well as 
doxorubicin (Doxo) and ATO or the inhibitors solvents in case of the negative controls for 96 h. For analysis 
cells were incubated with MTS-reagent and absorbance was measured at 490 nm. Negative controls were set to 
100 % viability and relative viability was calculated. Mean values were plotted from four independent 
experiments. Standard deviations are represented by black error bars (Results for single and double treatments 
correspond to results depicted in figure 19 and 21). Data presented in this figure was also published     
(Boehme et al., 2016 (1)). 
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Figure 23: Effect of combined etoposide, doxorubicin and ATO treatment on the viability of                  
MSC-2014-7 control cells. 0.5 x 104 cells/well MSC-2014-7 were sown into 96-well plates. After 24 h cells 
were treated with a triple combination, the single concentrations and the double combinations of etoposide 
(Eto) and ATO as well as  doxorubicin (Doxo) and ATO or the inhibitors solvents in case of the negative 
controls for 96 h. For analysis cells were incubated with MTS-reagent and absorbance was then measured 
at 490 nm. Negative controls were set to 100 % viability and the relative viability was calculated. Mean 
values were plotted from four independent experiments. Standard deviations are represented by black error 
bars (Results for single and double treatments correspond to results depicted in figure 20 and 22). Data 
presented in this figure was also published (Boehme et al., 2016 (1)). 
Summary 
Combination of etoposide and ATO, doxorubicin and ATO or all three drugs showed 
additive effects in all three EWS cell lines tested, whereas MSC were barely 
compromised. However, sensitivity to the individual drugs and combinatorial effects 
were very different between the cell lines. Moreover, the triple combination was not 
clearly superior compared to double combinations. 
 
3.3 Impact of ATO and cytostatics on the colony formation of Ewing 
sarcoma cell lines 
In the previous MTS assays a first analysis of the consequences of GANT61, ATO, 
etoposide and doxorubicin treatment of EWS cell lines was made. Apart from the 
influence of these inhibitors on the viability of cells, the ability to proliferate and to form 
colonies from single cells was analysed. As single cells have a lack of cell-cell contacts 
and soluble factors generated by their neighbour cells this assay simulates the process of 
metastasis in a very simple manner. The ability of single tumour cells to metastasise is 
fundamentally dependant on their ability to migrate but also their ability to proliferate 
again in a new environment. The reduction of colonies was examined in all three EWS 
cell lines treated with three different concentrations of GANT61, ATO, etoposide and 
doxorubicin and with a combination of etoposide and ATO as well as a combination of 
doxorubicin and ATO. 
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3.3.1 Effect of GANT61 and ATO on the colony formation of the Ewing sarcoma 
cell lines A673, RD-ES and SK-N-MC 
GANT61 
Both RD-ES (Figure 24B) and SK-N-MC cells (Figure 24C) were largely resistant to 
treatment with GANT61. A significant reduction of colony numbers could only be 
obtained with a dose of 20 µM GANT61. In A673 cells (Figure 24A) a concentration of 
10 µM GANT61 was already sufficient to decrease the amount of colonies and with         
15 µM only very few, small colonies remained, whereas 20 µM of GANT61 completely 
suppressed the ability of A673 cells to form colonies. 
 
Figure 24: Clonogenic assay of the EWS cell lines A673, RD-ES and SK-N-MC treated with GANT61.                            
A: 1 x 103 cells/well A673, B: 0.5 x 103 cells/well RD-ES or C: 0.5 x 103 cells/well SK-N-MC were sown 
into 6-well plates and treated with solvent only (negative control) or 10 µM, 15 µM or 20 µM GANT61 for 
72 h. Subsequently, every 72 h medium was replaced with fresh medium without inhibitor and cells were 
incubated until negative controls were grown. Colonies were then fixed with methanol and stained with 
crystal violet. For documentation results were photographed. 
Arsenic trioxide 
Figure 25 demonstrates that 0.5 µM ATO did not have a significant impact on the colony 
formation of any of the cell lines examined. 1 µM ATO reduced both colony number and 
size in RD-ES (Figure 25B) and A673 cells (Figure 25A). 3 µM ATO were sufficient to 
completely abolish colony formation of RD-ES cells and to largely prevent colony 
formation of A673 cells. Only SK-N-MC cells (Figure 25C) still formed a reduced 
number of colonies after treatment using 3 µM ATO. 
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Figure 25: Clonogenic assay of the EWS cell lines A673, RD-ES and SK-N-MC treated with ATO.                                     
A: 1 x 103 cells/well A673, B: 0.5 x 103 cells/well RD-ES or C: 0.5 x 103 cells/well SK-N-MC were sown 
into 6-well plates and treated with solvent only (negative control) or 0.5 µM, 1 µM or 3 µM ATO for 72 h. 
Subsequently, every 72 h medium was replaced with fresh medium without inhibitor and cells were 
incubated until negative controls were grown. Colonies were then fixed with methanol and stained with 
crystal violet. For documentation results were photographed. Data presented in this figure was also 
published (Boehme et al., 2016 (1)). 
3.3.2 Effect of etoposide and doxorubicin on the colony formation of the Ewing 
sarcoma cell lines A673, RD-ES and SK-N-MC 
Etoposide 
In comparison to the MTS assay results (chapter 3.2.1) lower concentrations of etoposide 
were needed for a significant reduction of colony growth. The number of RD-ES and    
SK-N-MC colonies (Figure 26B and C) decreased in a dose dependent manner starting 
at 0.2 µM etoposide with only few colonies persisting when treated with 0.3 µM 
etoposide. RD-ES cells formed no colonies under treatment with 0.5 µM etoposide, 
whereas one small SK-N-MC colony grew under this dose. In contrast, 0.2 µM etoposide 
had only a minor effect on A673 cells (Figure 26A). Though colony growth decreased 
dose dependently applying a dose of 0.3 µM etoposide and 0.5 µM etoposide, some 
colonies were still persisting at the highest dose applied. 
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Figure 26: Clonogenic assay of the EWS cell lines A673, RD-ES and SK-N-MC treated with etoposide. 
A: 1 x 103 cells/well A673, B: 0.5 x 103 cells/well RD-ES or C: 0.5 x 103 cells/well SK-N-MC were sown 
into 6-well plates and treated with solvent only (negative control) or 0.2 µM, 0.3 µM or 0.5 µM etoposide 
for 72 h. Subsequently, every 72 h medium was replaced with fresh medium without inhibitor and cells were 
incubated until negative controls were grown. Colonies were then fixed with methanol and stained with 
crystal violet. For documentation results were photographed. Data presented in this figure was also 
published (Boehme et al., 2016 (1)). 
Doxorubicin 
Figure 27 indicates a similar sensitivity of all three EWS cell lines to treatment with 
doxorubicin. As for etoposide, cells showed a significantly higher doxorubicin sensitivity 
in the colony formation assay compared to the MTS assay. Even 10 nM doxorubicin were 
sufficient for a very significant reduction of colony growth. For A673 and RD-ES cells 
15 nM doxorubicin were required for a complete suppression of their ability to form 
colonies (Figure 27A and B). Only SK-N-MC cells still formed some small colonies 
under treatment with 15 nM doxorubicin (Figure 27C). 
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Figure 27: Clonogenic assay of the EWS cell lines A673, RD-ES and SK-N-MC treated with doxorubicin.                     
A: 1 x 103 cells/well A673, B: 0.5 x 103 cells/well RD-ES or C: 0.5 x 103 cells/well SK-N-MC were sown 
into 6-well plates and treated with solvent only (negative control) or 5 nM, 10 nM or 15 nM doxorubicin 
for 72 h. Subsequently, every 72 h medium was replaced with fresh medium without inhibitor and cells were 
incubated until negative controls were grown. Colonies were then fixed with methanol and stained with 
crystal violet. For documentation results were photographed. Data presented in this figure was also 
published (Boehme et al., 2016 (1)). 
3.3.3 Effect of drug combinations on the colony formation of the Ewing sarcoma 
cell lines A673, RD-ES and SK-N-MC 
To examine any additive effects of the GLI inhibitor ATO and the cytostatics etoposide 
and doxorubicin four combinations of either etoposide with ATO or doxorubicin with 
ATO were examined in all three EWS cells lines. In order to ensure a better comparability 
between the cell lines each 0.5 µM and 1 µM ATO were combined with either 0.1 µM 
and 0.2 µM etoposide or 5 nM and 10 nM doxorubicin. 
Etoposide and Arsenic trioxide 
As presented in Figure 28A A673 cells showed a reduction of colony number using any 
of the combinations. Already combining 0.1 µM etoposide and 0.5 µM ATO showed an 
effect. When doubling the amount of etoposide to 0.2 µM the colony number remained 
stable, whereas the double amount of 1 µM ATO potentiated the effect. Compared to 
single treatments shown in Figure 25A and 26A inhibitor combinations were 
significantly more efficient in A673 cells.  
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In RD-ES (Figure 28B) and SK-N-MC cells (Figure 28C) treatment with 0.1 µM 
etoposide and 0.5 µM ATO had a visible impact on colony formation as well. Elevating 
the ATO or etoposide dose in RD-ES cells enhanced the suppression of colony formation 
with 0.2 µM etoposide and 1 µM ATO being sufficient for a complete inhibition. For 
comparison, under both single treatments colonies were persisting (Figure 25B and 
26B). In SK-N-MC cells elevation of the ATO dose was dominant over etoposide. Again, 
with the highest doses of 0.2 µM etoposide and 1 µM ATO applied no colony remained, 
which is once more clearly superior compared to the single treatments (Figure 25C and 
26C). 
 
Figure 28: Clonogenic assay of the EWS cell lines A673, RD-ES and SK-N-MC treated with a 
combination of etoposide and ATO. A: 1 x 103 cells/well A673, B: 0.5 x 103 cells/well RD-ES or                     
C: 0.5 x 103 cells/well SK-N-MC were sown into 6-well plates and treated with solvent only (negative 
control) or different inhibitor concentrations for 72 h. Subsequently, every 72 h medium was replaced with 
fresh medium without inhibitor and cells were incubated until negative controls were grown. Colonies were 
then fixed with methanol and stained with crystal violet. For documentation results were photographed. 
Data presented in this figure was also published (Boehme et al., 2016 (1)). 
Doxorubicin and Arsenic trioxide 
All three EWS cell lines presented a slight reduction of the number of colonies when 
treated with a combination of 5 nM doxorubicin and 0.5 µM ATO. The effect was more 
distinct in RD-ES cells (Figure 29B), where also the size of the remaining colonies was 
reduced. Moreover, in RD-ES 5 nM doxorubicin combined with 1 µM ATO were 
sufficient for a complete suppression of colony growth, which was clearly superior 
compared to single treatment (Figure 25B and 27B). The combination of 5 nM 
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doxorubicin and 0.5 µM ATO used on A673 cells led to a stronger reduction of colony 
formation compared to single treatment. However, two colonies could still be observed 
with 10 nM doxorubicin and 1 µM ATO being applied. Yet, also in A673 cells the drug 
combinations were more efficient compared to single administration (Figure 25A and 
27A). SK-N-MC cells (Figure 29C) were more sensitive to the combination of 
doxorubicin and ATO than A673, but a complete suppression of colony formation could 
only be obtained with a combination of 10 nM doxorubicin and 1 µM ATO. Again, all 
combinations exceeded the impact of single treatment (Figure 25C and 27C). 
 
Figure 29: Clonogenic assay of the EWS cell lines A673, RD-ES and SK-N-MC treated with a 
combination of doxorubicin and ATO. A: 1 x 103 cells/well A673, B: 0.5 x 103 cells/well RD-ES or               
C: 0.5 x 103 cells/well SK-N-MC were sown into 6-well plates and treated with solvent only (negative 
control) or different inhibitor concentrations for 72 h. Subsequently, every 72 h medium was replaced with 
fresh medium without inhibitor and cells were incubated until negative controls were grown. Colonies were 
then fixed with methanol and stained with crystal violet. For documentation results were photographed. 
Data presented in this figure was also published (Boehme et al., 2016 (1)). 
3.3.4 Summary 
As in the viability assays, A673 cells showed a greater sensitivity to GANT61 compared 
to RD-ES and SK-N-MC. The ATO sensitivity of colony formation in A673 and RD-ES 
cells was comparable. On the other hand, A673 cells were most resistant to etoposide. 
Only doxorubicin affected growth of all three EWS cell lines to the same extent. The 
combined treatment of the EWS cell lines using etoposide and ATO but also doxorubicin 
and ATO potentiated the suppression of colony formation achieved by the single 
substances. 
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3.4 Impact of GANT61, ATO, etoposide and doxorubicin on 3D 
spheroid cultures of Ewing sarcoma cell lines 
All previously used methods have only shown the drug effects on cells grown in 
monolayer. However, tumour cells in the human body grow in 3D structures and therefore 
have different cellular interactions but also access to oxygen, nutrients and drugs 
compared to the same cells grown in vitro in monolayers. Hence, the effect of GANT61, 
ATO and cytostatics was tested on cells growing in 3D spheroid cultures simulating 
conditions occurring in vivo. Using round bottom non-adherent 96-well-plates cells were 
grown for 4 days to establish spheroids which was photographically documented. Only 
the EWS cell lines SK-N-MCs and A673 were able to form and sustain spheroids for       
10 days, whereas RD-ES loosely concentrated at the bottom of the well and were therefore 
not used for further experiments (Figure 30). 
 
Figure 30: 3D spheroid formation of the EWS cell lines A673, RD-ES and SK-N-MC. 0.5 x 104 cells/well 
(A673 and RD-ES) or 0.25 x 104 cells/well (SK-N-MC) were sown into non-adherent-u-bottom 96-well 
plates. Spheroid formation was documented via light micrographs 4 days after seeding. 
 
3.4.1 Effect of GANT61 and ATO on A673 and SK-N-MC spheroid cultures 
Four days after plating growing spheroids from 0.5 x 104 cells/well (A673) or                           
0.25 x 104 cells/well (SK-N-MC) were treated with 10 µM or 15 µM GANT61, 
respectively 2 µM or 5 µM ATO for another 4 days. The negative controls were treated 
with the inhibitors solvent. 
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GANT61 
Figure 31 shows spheroids of SK-N-MC and A673 cells increasing in diameter after          
4 days irrespectively of GANT61 or solvent addition. Spheroid size was only minimally 
reduced upon GANT61 treatment. However, 15 µM GANT61 were sufficient to affect 
spheroid integrity of SK-N-MC cells, which indicates a decline in cellular cohesion. 
Integrity of A673 spheroids was minimally affected by 15 µM GANT61, showing a slight 
bulge in the spheroid surface. 
 
Figure 31: Effect of GANT61 on A673 and SK-N-MC cells growing in 3D spheroid cultures.                         
0.5 x 104 cells/well (A673) or 0.25 x 104 cells/well (SK-N-MC) were sown into non-adherent-u-bottom        
96-well plates and incubated for 4 days to allow spheroid formation. Spheroids were documented via light 
micrographs before treatment (0 d) and after four days of treatment (4 d) with the inhibitors solvent 
(DMSO) as a negative control or with 10 µM or 15 µM GANT61. All treatments were performed in 
quadruplicates with representative micrographs shown. 
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Arsenic trioxide 
As indicated in Figure 32, SK-N-MC and A673 spheroids treated with 2 µM ATO 
showed a significant growth suppression compared to the solvent treated control, which 
was only marginally reinforced applying a higher concentration of 5 µM ATO in             
SK-N-MC. Furthermore, ATO compromised spheroid integrity, which became 
particularly obvious in the A673 spheroids, but was also present in the SK-N-MC 
spheroids. 
 
Figure 32: Effect of ATO on A673 and SK-N-MC cells growing in 3D spheroid cultures.                                
0.5 x 104 cells/well (A673) or 0.25 x 104 cells/well (SK-N-MC) were sown into non-adherent-u-bottom        
96-well plates and incubated for 4 days to allow spheroid formation. Spheroids were documented via light 
micrographs before treatment (0 d) and after four days of treatment (4 d) with the inhibitors solvent (H2O) 
as a negative control or with 2 µM or 5 µM ATO. All treatments were performed in quadruplicates with 
representative micrographs shown. Data presented in this figure was also published                                
(Boehme et al., 2016 (1)). 
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3.4.2 Effect of etoposide and doxorubicin on A673 and SK-N-MC spheroid cultures 
Four days after plating growing spheroids from 0.5 x 104 cells/well (A673) or                            
0.25 x 104 cells/well (SK-N-MC) were treated with 2 µM or 5 µM etoposide, respectively    
30 nM or 50 nM doxorubicin for another 4 days. The negative control spheroids were 
incubated with the inhibitors solvent. 
Etoposide 
As presented in Figure 33, spheroid growth of both EWS cell lines was completely 
inhibited by 2 µM etoposide applied for 4 days. Spheroids grown from the cell line        
SK-N-MC showed a loss of cell surface integrity starting with 2 µM etoposide. With a 
concentration of 5 µM etoposide applied the spheroid structure was completely lost. 
Integrity of A673 spheroids was still retained upon etoposide administration, only a slight 
surface discontinuity could be seen. 
 
Figure 33: Effect of etoposide on A673 and SK-N-MC cells growing in 3D spheroid cultures.                                 
0.5 x 104 cells/well (A673) or 0.25 x 104 cells/well (SK-N-MC) were sown into non-adherent-u-bottom 96-well 
plates and incubated for 4 days to allow spheroid formation. Spheroids were documented via light micrographs 
before treatment (0 d) and after four days of treatment (4 d) with the inhibitors solvent (DMSO) as a negative 
control or with 2 µM or 5 µM etoposide. All treatments were performed in quadruplicates with representative 
micrographs shown. Data presented in this figure was also published (Boehme et al., 2016 (1)). 
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Doxorubicin 
A dose dependent decrease in spheroid growth as well as a destabilisation of the spheroid 
surface integrity was observed in the SK-N-MC spheroids treated with 30 nM and 50 nM 
doxorubicin. Also the size of the A673 spheroids was reduced by doxorubicin treatment, 
whereas spheroid integrity was barely affected showing detachment of some cells from 
the spheroids. 
 
Figure 34: Effect of doxorubicin on A673 and SK-N-MC cells growing in 3D spheroid cultures.               
0.5 x 104 cells/well (A673) or 0.25 x 104 cells/well (SK-N-MC) were sown into non-adherent-u-bottom        
96-well plates and incubated for 4 days to allow spheroid formation. Spheroids were documented via light 
micrographs before treatment (0 d) and after four days of treatment (4 d) with the inhibitors solvent 
(DMSO) as a negative control or with 30 nM or 50 nM doxorubicin. All treatments were performed in 
quadruplicates with representative micrographs shown. Data presented in this figure was also published 
(Boehme et al., 2016 (1)). 
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3.4.3 Summary 
3D spheroid cultures of both EWS cell lines SK-N-MC and A673 seemed to be largely 
resistant to treatment with GANT61. Using ATO or etoposide on the other hand, the lower 
concentration of 2 µM was sufficient to largely inhibit spheroid growth and to affect 
spheroid integrity in both cell lines. This effect was only slightly reinforced by application 
of a higher dose of ATO or etoposide. Doxorubicin treatment led to slight suppression of 
spheroid growth of both cell lines. Spheroid integrity was especially compromised in 
A673 cells. 
 
3.5 Effect of GANT61, ATO, etoposide and doxorubicin on cell death 
induction in Ewing sarcoma cell lines 
3.5.1 Detection of cell death using flow cytometry (FACS-analysis) 
All previously performed tests have demonstrated the impact of GANT61, ATO, 
etoposide and doxorubicin on the viability and proliferation of EWS cells. To determine 
whether the substances not only transiently compromise the cellular metabolism and 
arrest growth but also induce cell death, flow cytometry was performed using the “Fixable 
Viability Dye - eFluor® 450” for staining of cells. Only dying cells take up eFluor® 450 
as the dye cannot pass intact cellular membranes. The ratio between dye-positive and dye-
negative cells is therefore considered proportional to the rate of cell death in that cell 
population. 
In the following graphs the rate of cell death is shown for the EWS cell lines and         
MSC-2014-7 treated with selected concentrations of GANT61, ATO, etoposide, 
doxorubicin and combinations thereof. The highest concentrations applied were always 
tested on the control cells MSC-2014-7. 
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Effect of GLI-Inhibition using GANT61 and ATO on cell death induction of A673,  
RD-ES, SK-N-MC and MSC 
GANT61 
All three EWS cell lines as well as MSC-2014-7 were treated with 10 µM and 15 µM 
GANT61. No significant effect on cell death induction was observed. Only A673 cells 
showed at least 9 ± 2 % dead cells upon treatment with 15 µM GANT61 (Figure 35A). 
In SK-N-MC cells 5 ± 3 % dead cells were detected with 10 µM GANT61 but there was 
no further increase upon application of 15 µM (Figure 35C). GANT61 did not affect 
MSC-2014-7 (Figure 35D). Surprisingly some more living cells were present when     
RD-ES cells were treated with GANT61 though rates did not drop lower than -3 % 
(Figure 35B). 
 
Figure 35: Effect of GANT61 on cell death induction in the EWS cell lines A673, RD-ES and SK-N-MC 
in comparison to MSC-2014-7. A: 2.5 x 105 cells/well A673, B: 1.5 x 105 cells/well RD-ES,                               
C: 1 x 105 cells/well SK-N-MC or D: 2.5 x 105 cells/well MSC-2014-7 were sown out into 6-well plates. 
After 24 h cells were treated with 10 µM or 15 µM GANT61 or the inhibitor solvent for 72 h. Cells were 
then stained with eFluor® 450 and analysed by flow cytometry. Negative controls were set to 0 % cell 
death and the rate of cell death upon treatment using GANT61 calculated. Mean values were plotted from 
three independent replicates. Standard deviations are represented by black error bars. Data presented in 
this figure was also published (Boehme et al., 2016 (1)). 
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Arsenic trioxide 
Figure 36 shows cell death induction after treatment with ATO. All three EWS cell lines 
presented rates as high as 63 ± 1 % (A673), 41 ± 3 % (RD-ES) or 70 ± 0 % (SK-N-MC) 
under treatment with 5 µM ATO. Interestingly, concentrations up to 0.5 µM ATO did not 
raise cell death above 13 ± 2 % in A673 cells (Figure 36A). 1 µM ATO however, led to 
65 ± 0 % dye positive cells in A673, which could not be further enhanced by increasing 
ATO doses. RD-ES cells (Figure 36B) showed no cell death upon treatment with 1 µM 
ATO. However, 2 µM ATO were sufficient for 32 ± 5 % death cells, which was further 
enhanced by 3 µM ATO (44 ± 1 %). As in the MTS assay, SK-N-MC cells (Figure 36C) 
were most resistant with only 9 ± 1 % dead cells upon treatment with 2 µM ATO.            
SK-N-MC cells showed an increase in dead cells to 21 ± 3 % upon treatment with 3 µM 
ATO and 70 ± 0 %, the highest value obtained in the EWS cell lines with 5 µM ATO 
being applied. No significant uptake of eFluor® 450 was observed in MSC-2014-7 
(Figure 36D), levels of cell death ranging between -2 % and 2 % under treatment with 
the highest dose of 5 µM ATO. 
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Figure 36: Effect of ATO on cell death induction in the EWS cell lines A673, RD-ES and SK-N-MC in 
comparison to MSC-2014-7. A: 2.5 x 105 cells/well A673, B: 1.5 x 105 cells/well RD-ES,                                     
C: 1 x 105 cells/well SK-N-MC or D: 2.5 x 105 cells/well MSC-2014-7 were sown out into 6-well plates. 
After 24 h cells were treated with A673: 0.1 µM, 0.3 µM, 0.5 µM, 1 µM, 2 µM or 5 µM ATO; RD-ES:           
1 µM, 2 µM, 3 µM or 5 µM ATO; SK-N-MC: 2 µM, 3 µM or 5 µM ATO and MSC-2014-7; 0.5 µM, 1 µM, 
2 µM, 3 µM or 5 µM ATO or the inhibitor solvent for 72 h. Cells were then stained with eFluor® 450 and 
analysed by flow cytometry. Negative controls were set to 0 % cell death and the rate of cell death upon 
treatment using ATO was calculated. Mean values were plotted from three independent replicates. 
Standard deviations are represented by black error bars. Data presented in this figure was also published 
(Boehme et al., 2016 (1)). 
Effect of the cytostatics etoposide and doxorubicin on cell death induction of A673, 
RD-ES, SK-N-MC and MSC 
Etoposide 
Etoposide treated A673, RD-ES and SK-N-MC cells showed a dose dependent increase 
of cell death reaching the highest levels after application of 5 µM etoposide. In A673 cells 
(Figure 37A) 55 ± 2 % already lost their membrane integrity after treatment with 1 µM 
etoposide which reached up to 71 ± 1 % with 5 µM etoposide. Both RD-ES and                 
SK-N-MC cells were more resistant to etoposide, their ratio of eFluor® 450 positive cells 
being 21 ± 0 % (RD-ES) or 32 ± 4 % (SK-N-MC) after treatment with 2 µM etoposide. 
The amount of dead cells increased under 5 µM etoposide, obtaining 40 ± 1 % (RD-ES) 
and 39 ± 4 % (SK-N-MC). MSC-2014-7 were resistant to all etoposide concentrations 
applied showing maximal 2 ± 2 % dye positive cells after application of 2 µM etoposide 
(Figure 37D).  
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Figure 37: Effect of etoposide on cell death induction in the EWS cell lines A673, RD-ES and SK-N-MC 
in comparison to MSC-2014-7. A: 2.5 x 105 cells/well A673, B: 1.5 x 105 cells/well RD-ES,                               
C: 1 x 105 cells/well SK-N-MC or D: 2.5 x 105 cells/well MSC-2014-7 were sown out into 6-well plates. 
After 24 h cells were treated with A673: 1 µM, 2 µM or 5 µM etoposide; RD-ES: 0.5 µM, 2 µM or 5 µM 
etoposide; SK-N-MC: 0.5 µM, 1 µM, 2 µM or 5 µM etoposide and MSC-2014-7: 1 µM, 2 µM or 5 µM 
etoposide or the inhibitor solvent for 72 h. Cells were then stained with eFluor® 450 and analysed by flow 
cytometry. Negative controls were set to 0 % cell death and the rate of cell death upon treatment using 
etoposide was calculated. Mean values were plotted from three independent replicates. Standard deviations 
are represented by black error bars. Data presented in this figure was also published                              
(Boehme et al., 2016 (1)). 
Doxorubicin 
As presented in Figure 38A 30 nM doxorubicin were sufficient for a significant increase 
of the uptake of eFluor® 450 to 42 ± 3 % in A673 cells, whereas 5 nM had no noticeable 
effect (2 ± 3 %). A higher concentration of 50 nM doxorubicin led to 55 ± 1 % dead cells. 
In RD-ES cells a significant leap in eFluor® 450 uptake was achieved with 30 nM 
doxorubicin as well (26 ± 1 %) (Figure 38B), whereas lower concentrations led to poor 
rates dead cells (5 nM doxorubicin: 2 ± 2 %; 10 nM doxorubicin: 8 ± 1 %). 50 µM 
doxorubicin induced maximal cell death of 29 ± 2 % obtained for RD-ES cells. The effect 
of doxorubicin in SK-N-MC cells (Figure 38C) was more pronounced than in RD-ES 
cells. Levels of eFluor® 450 positive cells lay at 32 ± 2 % with 30 nM doxorubicin and 
increased to 41 ± 1 % upon treatment with 50 nM doxorubicin. Treatment of                  
MSC-2014-7 with 50 nM doxorubicin induced a maximum of 3 ± 3 % cell death      
(Figure 38D). 
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Figure 38: Effect of doxorubicin on cell death induction in the EWS cell lines A673, RD-ES and            
SK-N-MC in comparison to MSC-2014-7. A: 2.5 x 105 cells/well A673, B: 1.5 x 105 cells/well RD-ES,      
C: 1 x 105 cells/well SK-N-MC or D: 2.5 x 105 cells/well MSC-2014-7 were sown out into 6-well plates. 
After 24 h cells were treated with A673: 5 nM, 30 nM or 50 nM doxorubicin; RD-ES: 5 nM, 10 nM, 30 nM 
or 50 nM doxorubicin; SK-N-MC: 10 nM,    30 nM or 50 nM doxorubicin and MSC-2014-7: 30 nM or       
50 nM doxorubicin or the inhibitor solvent for 72 h. Cells were then stained with eFluor® 450 and analysed 
by flow cytometry. Negative controls were set to 0 % cell death and the rate of cell death upon treatment 
using doxorubicin was calculated. Mean values were plotted from three independent replicates. Standard 
deviations are represented by black error bars. Data presented in this figure was also published          
(Boehme et al., 2016 (1)). 
Effect of drug combinations on cell death induction in A673, RD-ES, SK-N-MC and 
MSC 
Etoposide, Doxorubicin and Arsenic trioxide 
For further enhancement of cell death two triple combinations consisting of etoposide, 
doxorubicin and ATO as well as the respective double combinations of etoposide and 
ATO and doxorubicin and ATO were applied to A673, RD-ES and SK-N-MC. The results 
are presented in Figure 39.  
As A673 (Figure 39A) were rather sensitive to low concentrations of 0.1 µM and 0.3 µM 
ATO in the MTS assay, these doses were combined with 1 µM etoposide or/and 5 nM 
doxorubicin. The death rate reached 56 ± 3 % upon combination of 1 µM etoposide and 
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0.1 µM ATO. However, 1 µM etoposide in single application also led to 55 ± 2 % dead 
cells. The same result was obtained with the higher ATO dose of 0.3 µM combined with 
1 µM etoposide, inducing 58 ± 3 % cell death. The uptake of eFluor® 450 seemed to be 
mostly dependent of the dose of etoposide applied. Regarding the combination of 
doxorubicin and ATO, 5 nM doxorubicin and 0.1 µM ATO presented a slightly higher 
level of eFluor® 450 positive cells in combination (9 ± 2 %) than in single treatment        
(5 nM doxorubicin: 2 ± 3 %; 0.1 µM ATO: 2 ± 1 %). In single application, increasing the 
ATO concentration to 0.3 µM 7 ± 1 % cells lost their membrane integrity. In combination 
with 5 nM doxorubicin however, an uptake of eFluor® 450 in 39 ± 3 % of the cells could 
be observed (Figure 39A). Unfortunately, in both triple combinations neither the 
combination of 1 µM etoposide and 5 nM doxorubicin with 0.1 µM ATO (53 ± 3 %) nor 
with 0.3 µM ATO (58 ± 2 %) produced death rates significantly above those of etoposide 
only or the double combination of etoposide and ATO.  
In RD-ES cells (Figure 39B) a significant rise of eFluor® 450 positive cells to 49 ± 3 % 
was achieved with a combination of 0.5 µM etoposide and 2 µM ATO, whereas single 
treatment led to 14 ± 1 % dead cells (0.5 µM etoposide) or 32 ± 5 % dead cells (2 µM 
ATO). Neither the combination of 5 nM doxorubicin with 2 µM ATO nor the combination 
of 10 nM doxorubicin with 2 µM AO did significantly elevate the amount of dead cells 
(5 nM doxorubicin / 2 µM ATO: 33 ± 1 %; 10 nM doxorubicin / 2 µM ATO: 37 ± 3 %) 
above the percentage obtained with ATO alone (32 ± 5 %), whereas single treatment with 
5 nM doxorubicin led to 2 ± 2 % and 10 nM doxorubicin to 8 ± 1 % dead cells. As A673 
cells, RD-ES cells presented no higher levels of cell death (32 ± 5 %) upon triple treatment 
with 0.5 µM etoposide, 5 nM doxorubicin and 2 µM ATO than in the combination with 
equal concentrations of etoposide and ATO (0.5 µM etoposide / 2 µM ATO: 49 ± 3 %). 
Although the dose of doxorubicin was increased to 10 nM in the second triple 
combination with etoposide and ATO, no further increase in cell death (46 ± 2 %) was 
obtained. 
In SK-N-MC cells (Figure 39C) combination of 0.5 µM etoposide and 3 µM ATO were 
required to increase the uptake of eFluor® 450 to 35 ± 8 % compared to single treatment 
with 0.5 µM etoposide (17 ± 1 %) or 3 µM ATO (21 ± 3 %). Doubling the dose of 
etoposide in combination to 1 µM etoposide showed no increase of the death rate                
(1 µM etoposide / 3 µM ATO: 34 ± 1 %) in comparison to single treatment                              
(1 µM etoposide: 27 ± 3 %). The treatment with 10 nM doxorubicin and 3 µM ATO        
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(28 ± 5 %) led to a slightly higher uptake of eFluor® 450 compared to 10 nM doxorubicin 
(12 ± 2 %) or 3 µM ATO (21 ± 3 %) only. Similar to A673 and RD-ES cells, SK-N-MC 
cells achieving no higher ratio of eFluor® 450 positive cells under triple treatment          
(0.5 µM etoposide / 30 nM doxorubicin and 3 µM ATO: 28 ± 3 %) than under combined 
treatment with either 0.5 µM etoposide and 3 µM ATO or 20 nM doxorubicin and 3 µM 
ATO. Even doubling the dose of etoposide to 1 µM did not increase the rate of cell death 
in triple treatment (1 µM etoposide / 30 nM doxorubicin / 3 µM ATO: 31 ± 0 %). 
For control, the highest etoposide, doxorubicin and ATO concentrations used in EWS cell 
lines were applied to MSC-2014-7 (Figure 39D). MSC did not reach a ratio of         
eFluor® 450 positive cells greater than 3 % neither in the double applications nor the 
triple combination of 1 µM etoposide, 30 nM doxorubicin and 3 µM ATO (Figure 39D). 
 
 
Figure 39: Effect of combined treatment with etoposide, doxorubicin and ATO on cell death induction 
in the EWS cell lines A673, RD-ES and SK-N-MC in comparison to MSC-2014-7. A: 2.5 x 105 cells/well 
A673, B: 1.5 x 105 cells/well RD-ES, C: 1 x 105 cells/well SK-N-MC or D: 2.5 x 105 cells/well                     
MSC-2014-7 were sown out into 6-well plates. After 24 h cells were treated with single doses or double 
and triple combinations of etoposide, doxorubicin and ATO or the inhibitor solvents for 72 h as indicated. 
Cells were then stained with eFluor® 450 and analysed by flow cytometry. Negative controls were set to 0 
% cell death and the rate of cell death upon treatment was calculated. Mean values were plotted from three 
independent replicates. Standard deviations are represented by black error bars. Data presented in this 
figure was also published (Boehme et al., 2016 (1)). 
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Summary 
All EWS cell lines were resistant to doses up to 15 µM GANT61, with cell death not 
exceeding 9 % obtained in A673. Upon treatment with ATO, etoposide and doxorubicin 
A673 cells were the most sensitive of the three EWS cell lines. Maximum apoptosis rates 
received with single treatments ranged from 44 % (3 µM ATO) in RD-ES to 71 %              
(5 µM etoposide) in A673 and 70 % (5 µM ATO) in SK-N-MC. Combined treatment of 
A673 or SK-N-MC cells with etoposide and ATO did not significantly exceed the death 
rate obtained with etoposide alone. Only in RD-ES cells the combined treatment of 
etoposide ATO was clearly superior compared to the single doses. Using doxorubicin and 
ATO in the combined treatment of RD-ES cells as well as SK-N-MC cells the death rate 
was clearly dependent on the ATO dose applied and did not exceed single application. 
Only in A673 cells combination of 5 nM doxorubicin and 0.3 µM ATO was more efficient 
compared to the single treatment. A triple treatment with both cytostatics and ATO could 
not clearly enhance cell death compared to the combination of etoposide and ATO in any 
of the EWS cell lines, whereas cell death upon combination of doxorubicin with ATO 
was below that of triple treatment with equal doses in A673 and SK-N-MC cells. 
Fortunately, the control cells MSC-2014-7 were resistant to all single concentrations of 
GANT61, ATO, etoposide and doxorubicin as well as the combinations of etoposide, 
doxorubicin and ATO applied. 
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3.5.2 Detection of apoptosis induction by caspase 3 and PARP cleavage in Ewing 
sarcoma cell lines 
As the FACS dye eFluor® 450 passes into all cells with a non-intact membrane, a 
distinction between apoptotic and necrotic cells cannot be made. However, cleaved PARP 
and caspase 3 are specific for apoptosis. Therefore, levels of both cleaved proteins where 
measured by western blot. 
Effect of ATO and GANT61 on apoptosis induction in A673, RD-ES, SK-N-MC and 
MSC 
GANT61 
Both cleaved PARP (89 kDa) and cleaved caspase 3 (17 kDa) bands were found in 
GANT61 treated A673 cells (Figure 40; lanes 5 - 6). The cleavage increasing in a dose 
dependant manner after treatment with 10 µM and 15 µM GANT61 compared to the 
negative control. Neither cleaved caspase 3 nor cleaved PARP could be detected in       
RD-ES cells using the same GANT61 concentrations (Figure 40; lanes 11 - 12), whereas 
in SK-N-MC cells very faint caspase 3 bands appeared (Figure 40; lanes 16 - 18).               
A cleaved PARP band was barely visible in SK-N-MC after incubation with 15 µM 
GANT61. However, quantification revealed no significant increase of either caspase 3 or 
PARP cleavage normalised to tubulin in both RD-ES and SK-N-MC cells after GANT61 
treatment in comparison to the negative control, whereas quantification verified the dose 
dependent increase of caspase 3 and PARP cleavage in A673 cells. After longer 
exposition of the RD-ES and SK-N-MC membranes also in MSC control cells two faint 
higher molecular weight bands were detected with the PARP antibody. A very slight 
caspase 3 (17 kDa) signal could be seen in Figure 40 lanes 13 - 14 after long exposition. 
Quantification showed low levels of caspase 3 and PARP cleavage in MSC after treatment 
with both GANT61 concentrations. 
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Figure 40: PARP and caspase 3 cleavage after GANT61 treatment of the EWS cell lines A673, RD-ES 
and SK-N-MC in comparison to MSC-2014-7. 1.5 x 104 cells/well of A673, RD-ES, SK-N-MC or           
MSC-2014-7 were sown into 12-well plates. After 24 h cells were treated with 10 µM GANT61, 15 µM 
GANT61 or the inhibitors solvent for 48 h. Proteins were isolated and their concentration was determined 
with Bradford assay. For the Western blot protein samples were loaded as follows: lane 1, 7, 13:              
MSC-2014-7 negative control; lane 2, 8, 14: MSC-2014-7 10 µM GANT61; lane 3, 9, 15: MSC-2014-7 15 
µM GANT61; lane 4, 10, 16: EWS cell line negative control; lane 5, 11, 17: EWS cell line 10 µM GANT61; 
lane 6, 12, 18: EWS cell line 15 µM GANT61, with lanes 4 - 6: A673, lanes 10 - 12: RD-ES and lanes         
16 - 18: SK-N-MC cells. Proteins were separated by SDS-PAGE and blotted onto a PVDF membrane. 
Membranes were incubated with primary antibodies against ß-tubulin, cleaved PARP and cleaved caspase 
3 overnight. A horseradish peroxidase-conjugated secondary antibody was used. ECL substrate was added 
to the membranes and chemiluminescence signals were recorded on a film. ImageJ was utilised for western 
blot quantification. Data presented in this figure was also published (Boehme et al., 2016 (1)). 
Arsenic trioxide 
ATO led to a dose dependent PARP and caspase 3 cleavage in A673 cells (Figure 41; 
lanes 5 - 6). Furthermore, A673 cells also exhibited cleaved PARP at low levels when 
treated with solvent only (Figure 41; lane 4). In RD-ES cells only after application of      
5 µM ATO a very faint band of cleaved PARP was visible (Figure 41; lane 11). However, 
quantification showed no increase in cleavage of PARP or caspase 3 in ATO treated      
RD-ES cells compared to the negative control. SK-N-MC cells presented both bands of 
cleaved PARP and caspase 3 upon treatment with 2 µM and 5 µM ATO. Quantification 
revealed that upon application of 5 µM ATO (Figure 41; lanes 17 - 18) cleavage of PARP 
was slightly enhanced, whereas caspase 3 cleavage was comparable to that of 2 µM ATO 
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treated cells. As shown in Figure 41, again two higher molecular weight bands appeared 
with the PARP antibody in MSC. Moreover, on the A673 blot MSC showed bands of 
cleaved caspase 3 in ATO treated samples. 
 
 
Figure 41: PARP and caspase 3 cleavage after ATO treatment of the EWS cell lines A673, RD-ES and 
SK-N-MC in comparison to MSC-2014-7. 1.5 x 104 cells/well of A673, RD-ES, SK-N-MC or MSC-2014-7 
were sown into 12-well plates. After 24 h cells were treated with 2 µM ATO, 5 µM ATO or the inhibitors 
solvent for 48 h. Proteins were isolated and their concentration was determined with Bradford assay. For 
the Western blot protein samples were loaded as follows: lanes 1, 7, 13: MSC-2014-7 negative control; 
lanes 2, 8, 14: MSC-2014-7 2 µM ATO; lanes 3, 9, 15: MSC-2014-7 5 µM ATO; lanes 4, 10, 16: EWS cell 
line negative control; lanes 5, 11, 17: EWS cell line 2 µM ATO; lanes 6, 12, 18: EWS cell line 5 µM ATO 
with lanes 4 - 6: A673, lanes 10 - 12: RD-ES and lanes 16 - 18: SK-N-MC cells. Proteins were separated 
by SDS-PAGE and blotted onto a PVDF membrane. Membranes were incubated with primary antibodies 
against ß-tubulin, cleaved PARP and cleaved caspase 3 overnight. A horseradish peroxidase-conjugated 
secondary antibody was used. ECL substrate was added to the membranes and chemiluminescence signals 
were recorded on a film. ImageJ was utilised for western blot quantification. Data presented in this figure 
was also published (Boehme et al., 2016 (1)). 
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Effect of the cytostatics etoposide and doxorubicin on apoptosis induction of A673,  
RD-ES, SK-N-MC and MSC 
Etoposide 
Etoposide induced both PARP and caspase 3 cleavage in all EWS cell lines (Figure 42). 
Already 2 µM etoposide were sufficient for apoptosis induction, whereas bands were 
weaker upon treatment with 5 µM, which however also corresponded to decreased             
ß-tubulin signals in all EWS cell lines. In A673 cells some cleaved PARP and caspase 3 
was already present in the solvent treated sample (Figure 42; lane 4). A faint band of 
cleaved caspase 3 also appeared in solvent treated SK-N-MC cells (Figure 42; lane 16). 
Quantification data proved a significant increase of cleaved caspase 3 and PARP in all 
EWS cell lines treated with 2 µM etoposide. A further increase after treatment with 5 µM 
etoposide was only detectable for cleaved PARP in RD-ES cells (Figure 42;                   
lanes 11 - 12). In A673 cells cleavage of caspase 3 decreased by half after treatment with 
5 µM etoposide compared to 2 µM etoposide (Figure 42; lanes 5 - 6) and an even higher 
decline of cleaved PARP was present in SK-N-MC cells treated with 5 µM etoposide 
compared to the lower dose (Figure 42; lanes 17 - 18). Under treatment with etoposide 
cleaved caspase 3 was barely detectable in any of the MSC-2014-7 samples, whereas 
again weak bands with higher molecular weight compared to PARP in the EWS cell lines 
were present in treated and non-treated MSC-2014-7 samples. However, no increase in 
PARP cleavage compared to the solvent treated MSC was found, as well as only a slight 
increase in cleaved caspase 3 in one blot with 5 µM etoposide. 
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Figure 42: PARP and caspase 3 cleavage after etoposide treatment of the EWS cell lines A673, RD-ES 
and SK-N-MC in comparison to MSC-2014-7. 1.5 x 104 cells/well of A673, RD-ES, SK-N-MC or            
MSC-2014-7 were sown into 12-well plates. After 24 h cells were treated with 2 µM etoposide, 5 µM 
etoposide or the inhibitors solvent for 48 h. Proteins were isolated and their concentration was determined 
with Bradford assay. For the Western blot protein samples were loaded as follows: lanes 1, 7, 13:            
MSC-2014-7 negative control; lanes 2, 8, 14: MSC-2014-7 2 µM etoposide; lanes 3, 9, 15: MSC-2014-7    
5 µM etoposide; lanes 4, 10, 16: EWS cell line negative control; lanes 5, 11, 17: EWS cell line 2 µM 
etoposide; lanes 6, 12, 18: EWS cell line 5 µM etoposide with lanes 4 - 6: A673, lanes 10 - 12: RD-ES and 
lanes 16 - 18: SK-N-MC cells. Proteins were separated by SDS-PAGE and blotted onto a PVDF membrane. 
Membranes were incubated with primary antibodies against ß-tubulin, cleaved PARP and cleaved     
caspase 3 overnight. A horseradish peroxidase-conjugated secondary antibody was used. ECL substrate 
was added to the membranes and chemiluminescence signals were recorded on a film. ImageJ was utilised 
for western blot quantification. Data presented in this figure was also published (Boehme et al., 2016 (1)). 
Doxorubicin 
RD-ES and SK-N-MC cells showed very low amounts of cleaved caspase 3 (17 kDa) in 
doxorubicin treated samples (Figure 43). In A673 cells bands of the tubulin loading 
control were also intensified upon etoposide treatment (Figure 43; lanes 4 - 6). A pale 
band could additionally be seen in the negative control of SK-N-MC cells. Quantification 
showed a dose dependent increase of caspase 3 as well as PARP cleavage in all three 
EWS cells lines. However, the response was weak compared to etoposide. Especially      
30 nM doxorubicin had comparable effects in MSC. Only after treatment with 50 nM 
doxorubicin the increase in both cleaved PARP and caspase 3 in EWS cells exceeded the 
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increase in MSC samples. In MSC-2014-7 again higher molecular weight bands were 
detected with the PARP antibody, but no cleaved caspase 3 (Figure 43). ß-tubulin was 
expressed in all samples with no distinct decline upon doxorubicin treatment. 
 
 
Figure 43: PARP and caspase 3 cleavage after doxorubicin treatment of the EWS cell lines A673,         
RD-ES and SK-N-MC in comparison to MSC-2014-7. 1.5 x 104 cells/well of A673, RD-ES, SK-N-MC or 
MSC-2014-7 were sown into 12-well plates. After 24 h cells were treated with 30 nM doxorubicin, 50 nM 
doxorubicin or the inhibitors solvent for 48 h. Proteins were isolated and their concentration was 
determined with Bradford assay. For the Western blot protein samples were loaded as follows: lanes            
1, 7, 13: MSC-2014-7 negative control; lanes 2, 8, 14: MSC-2014-7 30 nM doxorubicin; lanes 3, 9, 15: 
MSC-2014-7 50 nM doxorubicin; lanes 4, 10, 16: EWS cell line negative control; lanes 5, 11, 17: EWS cell 
line 30 nM doxorubicin; lanes 6, 12, 18: EWS cell line 50 nM doxorubicin with lanes 4 - 6: A673, lanes   
10 - 12: RD-ES and lanes 16 - 18: SK-N-MC cells. Proteins were separated by SDS-PAGE and blotted onto 
a PVDF membrane. Membranes were incubated with primary antibodies against ß-tubulin, cleaved PARP 
and cleaved caspase 3 overnight. A horseradish peroxidase-conjugated secondary antibody was used. ECL 
substrate was added to the membranes and chemiluminescence signals were recorded on a film. ImageJ 
was utilised for western blot quantification. Data presented in this figure was also published                
(Boehme et al., 2016 (1)). 
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Summary 
GANT61 treatment induced PARP and caspase 3 cleavage in A673 cells, whereas         
RD-ES and SK-N-MC were almost not compromised. ATO induced caspase 3 and PARP 
dependent apoptosis both in A673 and SK-N-MC cells. Neither cleaved PARP nor 
cleaved caspase 3 was detected in ATO treated RD-ES cells, which were however dying 
upon ATO treatment as determined by loss of membrane integrity (Figure 36). Under 
treatment with etoposide both cleaved PARP and caspase 3 were induced in all three EWS 
cell lines, whereas the effect with doxorubicin was less distinct. 
 
3.6 Influence of ATO on GLI1 protein expression in A673, RD-ES and 
SK-N-MC cells in comparison to MSC 
ATO has been reported to influence GLI expression in several papers. As the drug has 
presented a high specificity to the EWS cell lines in all experiments the influence ATO 
has on the GLI1 protein expression is of special interest. 
Figure 44 shows GLI1 protein levels in the three EWS cell lines in comparison to MSC 
after treatment with two ATO concentrations. RD-ES and SK-N-MC were exposed to      
2 µM and 5 µM ATO, whereas for A673, being more sensitive to ATO, 0.5 µM and            
1 µM ATO were used. MSC-2014-7 cells were treated with equivalent concentrations for 
direct comparison. GLI1 protein levels of the negative controls were set to 100 %. Full 
length GLI1 protein (≥ 100 kDa) was detected in all MSC-2014-7 samples. Application 
of 0.5 µM (Figure 44; lane 2) and 1 µM ATO (Figure 44; lane 3) on MSC led to a slight 
increase of GLI1 protein abundance compared to solvent treated cells (0.5 µM ATO:     
143 % and 1 µM ATO: 122 %) (Figure 44; lane 1). However, when treated with 2 µM 
(Figure 44; lanes 8 and 14) and 5 µM ATO (Figure 44; lanes 9 and 15) GLI1 abundance 
was reduced in MSC to 74 % or 49 % (with 2 µM ATO) and 64 % or 52 % (with 2 µM 
ATO). All EWS cell lines showed a significant increase in GLI1 protein under ATO 
treatment. In A673 cells 0.5 µM ATO induced GLI1 to 359 %, but 1 µM ATO (107 %) 
presented GLI1 protein levels compared to the negative control. In RD-ES and                 
SK-N-MC both concentrations enhanced GLI1 protein levels. RD-ES cells showed more 
increased GLI1 abundance after treatment with the lower ATO dose of 2 µM (227 %), 
compared to 5 µM ATO (167 %), whereas GLI1 protein levels in SK-N-MC cells 
increased with rising ATO concentrations (2 µM ATO: 159 %; 5 µM ATO: 230 %). 
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Figure 44: Expression of GLI1 protein after ATO treatment of the EWS cell lines A673, RD-ES and   
SK-N-MC as well as MSC-2014-7. 1.5 x 104 cells/well of A673, RD-ES, SK-N-MC or MSC-2014-7 were 
sown into 12-well plate and treated with 0.5 µM and 1 µM ATO (A673), 2 µM and 5 µM ATO (RD-ES and 
SK-N-MC) or the inhibitor solvent for control. After 48 h proteins were isolated and their concentration 
was measured with Bradford assay. For the western blot protein samples were loaded as follows: lanes     
1, 7, 13: MSC-2014-7 negative control; lane 2: MSC-2014-7 0.5 µM ATO; lane 3: MSC-2014-7 1 µM ATO; 
lanes 8 and 14: MSC-2014-7 2 µM ATO; lanes 9 and 15: MSC-2014-7 5 µM ATO; lanes 4, 10, 16: EWS 
cell line negative control; lane 5: A673 0.5 µM ATO; lane 6: A673 1 µM ATO; lanes 11 and 17: RD-ES, 
respectively SK-N-MC 2 µM ATO; lanes 12 and 18: RD-ES, respectively SK-N-MC 5 µM ATO. Proteins 
were separated by SDS-PAGE and blotted onto a PVDF membrane. Membranes were incubated with the 
primary antibodies GLI1 rabbit mAb or tubulin rabbit mAb overnight. A horseradish                        
peroxidase-conjugated anti-rabbit pAb was used as secondary antibody. ECL substrate was added to the 
membranes chemiluminescence signals were recorded on a film. ImageJ was utilised for western blot 
quantification.  
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4 Discussion 
Despite intensive therapy, mortality in patients with EWS is still very high. Even though 
5-year survival rates after standard therapy of the local type of EWS are around 70 % 
(Esiashvili et al., 2008), patients with metastatic high-risk EWS treated with VIDE 
chemotherapy, which includes doxorubicin and etoposide, only show a 5-year survival of 
20-30 % (Jiang et al., 2015a). Furthermore, drug resistance often occurs after first-line 
therapy, leading to a selection of more resistant tumour cells (May et al., 2013). Therefore, 
new therapeutic alternatives to the currently established chemotherapy, radiation and 
surgery are needed for overcoming the common drug resistance. 
I focused on a new approach involving the inhibition of the Hh signalling pathway, as 
aberrant Hh activation has been observed in several cancers including EWS (Amakye et 
al., 2013; Joo et al., 2009; Kelleher et al., 2012). Aberrant Hh signalling correlates with 
cancer formation and progression and could lead to drug resistance by abundant 
expression of the ABC transporter MRP1 (Oda et al., 1997). 
 
4.1 Hh signalling in Ewing sarcoma cell lines 
The EWS-FLI1 fusion protein typically expressed in Ewing sarcoma is known to 
modulate the expression of genes involved in multiple signalling pathways including the 
Hh pathway (Taylor et al., 2011). Previous studies have identified the GLI1 protein as a 
direct transcriptional target of EWS-FLI1 (Beauchamp et al., 2009). As GLI1 can be 
specifically targeted by different inhibitors, the expression of GLI1 was of special interest 
in this work. Furthermore, GLI1 transcriptionally targets GLI2, which is also known to 
be inhibited by ATO (Raju, 2011). Therefore, GLI1 and GLI2 basal expression was 
analysed both at mRNA and protein levels. Moreover, the mRNA expression of additional 
pathway components such as GLI3, SMO and PTCH was examined. 
Although Beauchamp et al. identified GLI1 as direct transcriptional target of the fusion 
protein EWS-FLI1 and showed its expression in several EWS cell lines including A673 
(Beauchamp et al., 2009), in this work only A673 expressed significantly higher levels of 
GLI1 mRNA in comparison to MSC, whereas SK-N-MC presented lower levels than 
MSC. Moreover, the high levels of GLI1 mRNA in A673 could not be confirmed at 
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protein levels by western blot. However, mRNA levels are also influenced by other 
factors such as mRNA stability and protein expression underlies complex regulation 
(Payne, 2015). Therefore, differences between mRNA and protein levels are common. 
None of the three EWS cell lines presented higher levels of GLI1 protein compared to 
MSC although they are suspected to be the cells of EWS origin (Lin et al., 2011; Sand et 
al., 2015). Furthermore, other bands presenting lower molecular weights were found 
using the GLI1 antibody in all EWS cell lines and MSC, including a very dominant band 
running at 45 - 55 kDa in the MSC-2014-7 lane. These could represent degraded products 
of GLI1 with a lower molecular weight or unspecific bindings of the GLI1 antibody. 
However, further evaluation using antibodies binding other epitopes of GLI1 may reveal 
whether this band is GLI1 specific. GLI2 also initiating GLI1 transcription (Hanna and 
Shevde, 2016) was only slightly higher expressed at mRNA level in A673 compared to 
MSC whereas expression in RD-ES and SK-N-MC cells was similar to MSC. 
Furthermore, the elevated GLI2 mRNA levels in A673 could not be confirmed by protein 
expression using western blot, where all three EWS cell lines presented a significantly 
reduced amount of both full length GLI2 and the repressor form compared to MSC. 
Even though all EWS cell lines presented lower levels of GLI1 and GLI2 protein 
compared to MSC this does not mean that survival and proliferation of EWS is not 
dependent on these proteins. The role GLI2 expression plays in EWS is currently 
undergoing analysis by Christensen et al., who have already found that GLI2 in EWS 
cells shows similar biologic effects than GLI1 and that knockdown of GLI2 compromises 
EWS cells (Christensen and May, 2016). 
In EWS the EWS-FLI1 induced GLI1 expression appears to be independent of classical 
upstream stimulation of the Hh pathway. Therefore, Hh pathway inhibition upstream of 
GLI1 by means of SMO or PTCH1 has not been effective (Joo et al. 2009, Zwerner et al. 
2008), although in this work SMO, GLI3 and PTCH1 mRNA could be found in all EWS 
cell lines, indicating presence of upstream pathway components. 
The three EWS cell lines showed no common mRNA expression profiles of Hh pathway 
genes. Concerning GLI1 and GLI2 protein expression in comparison to MSC, however 
all EWS cell lines were comparable. 
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4.2 GANT61 and ATO - GLI inhibition in Ewing sarcoma 
Aberrant activation of the Hh signalling pathway has been shown to correlate with the 
emergence of basal cell carcinoma (Bale and Yu, 2001; Johnson et al., 1996), 
medulloblastoma (Berman et al., 2002), RMS (Oue et al., 2013) and EWS (Beauchamp 
et al., 2011; Jung et al., 2006; Mathieu and Besancon, 2006; Smith et al., 2012). It has 
been described, that activation of the Hh pathway has influence on drug resistance 
mechanisms, due to the GLI-dependent regulation of ABC-transporter genes (Das et al., 
2013; Singh et al., 2011). Furthermore, inhibition of the Hh pathway in cells of different 
cancer types has been proven to reduce proliferation and induce apoptosis in several 
studies (Agyeman et al., 2014; Hu et al., 2009; Rudin, 2012). As described in chapter 
1.3.3 The Hedgehog pathway in Ewing sarcoma, the fusion protein EWS-FLI1 typically 
expressed in EWS interacts with the Hh pathway downstream of SMO and PTCH by 
direct transactivation of GLI1 (Beauchamp et al., 2009). Therefore, it is not surprising 
that the inhibition upstream of GLI1 has not been effective in EWS (Joo et al., 2009; 
Zwerner et al., 2008). As GLI1 and GLI2 expression could be confirmed with mRNA and 
on protein levels in all three EWS cell lines, direct targeting of GLI may be an option for 
future EWS treatment (Guo et al., 2006). 
 
4.2.1 GANT61 
GANT61 has been described to block both GLI1 and GLI2 mediated transcription 
(Agyeman et al., 2014; Lauth et al., 2007), thereby leading to cell cycle arrest, increased 
cell death as well as inhibition of DNA repair and cell migration (Gonnissen et al., 2015). 
These cytotoxic effects were apparent in cancer cell lines of various origin including RMS 
where first preclinical studies are being made (Agyeman et al., 2014; Boehme et al.,    
2016 (2)). With IC50 values of 12.01 µM (A673), 35.37 µM (RD-ES) and 59.56 µM            
(SK-N-MC), the EWS cell lines presented various responses to GANT61. Matsumoto et 
al. who also treated EWS cell lines with GANT61 achieved an IC50 value of 18.3 µM 
with SK-N-MC using MTS assays, which is significantly below the IC50 value for          
SK-N-MC in this work (Matsumoto et al., 2014). However, there were not many 
intermediate values in their growth curve, impeding precise results. Moreover, mutations 
can occur in cell lines during cultivation in vitro, by which sensitivity to drugs may differ 
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between laboratories and in time. Furthermore, cultivation and MTS assay procedure 
differed slightly from methods used in this work. In 3D spheroid culture both SK-N-MC 
and A673 were resistant to treatment up to 15 µM GANT61 and both RD-ES and            
SK-N-MC were barely compromised in their ability to form colonies. Neither EWS cell 
lines nor MSC presented significant levels of cell death in flow cytometry using 15 µM 
GANT61 and both RD-ES and SK-N-MC presented no PARP or caspase 3 cleavage.  
Indeed, RD-ES and SK-N-MC to GANT61 have low protein levels of GLI1 and GLI2 
compared to MSC as described in chapter 4.1. As GANT61 is a GLI1 and GLI2 inhibitor, 
high levels of these proteins may correlate with a higher sensitivity of cellular metabolism 
to this drug. This has already been shown in other studies with several tumours, including 
RMS (Srivastava et al., 2014), neuroblastoma (Wickström et al., 2013) and lung cancer 
(Huang et al., 2014). 
Interestingly, only the EWS cell line A673 showed cleaved PARP and cleaved caspase 3 
bands upon GANT61 treatment and was also the only cell line that was more sensitive in 
the MTS assay compared to the control cells MSC. Furthermore, A673 were significantly 
compromised using doses of GANT61 below 20 µM in colony growth. Equal results 
concerning A673 were made by Joo et al. with GANT58 which inhibited anchorage 
independent growth in A673 cells with doses of 5 µM GANT58 (Joo et al., 2009). As 
A673 showed GLI protein levels comparable to RD-ES and SK-N-MC, the higher 
sensitivity is not explained by this. For some reason A673 may be more dependent on 
availability of functional GLI1 and GLI2 proteins or off-target effects might play a 
significant role in this cell line. For instance, Geng et al. found GANT61 to down-regulate 
p-STAT3 and SOCS3 and thereby induce anti-tumour efficacy in T-cell lymphoma cells 
(Geng et al., 2016). Additionally, GANT61 induced apoptosis can also be dependent on 
an increased release of ROS from the mitochondria (Gonnissen et al., 2015; Lim et al., 
2015). However, cell death was not observed in GANT61 treated A673 cells by flow 
cytometry, although PARP and caspase 3 cleavage was present. 
As GANT61 did not selectively compromise the EWS cell lines in either viability, colony 
formation or apoptosis compared to MSC, the substance was not included in later analysis 
of combined treatment. 
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4.2.2 ATO 
ATO has been described to interact with both GLI1 and GLI2, thereby mediating 
degradation of the GLI proteins which prevents the activation of GLI1 and GLI2 target 
genes (Beauchamp et al., 2011; Kim et al., 2013), leading to cell cycle arrest, increased 
death of cells and viability loss. These cytotoxic effects were apparent in various cancers 
including EWS. In vitro tests by Zhang et al. using ATO in A673 and RD-ES cells led to 
an inhibition of migration and invasion (Zhang et al., 2012) and even an EWS xenograft 
model was compromised by ATO (Beauchamp et al., 2011; Kim et al., 2010). However, 
other in vivo studies found no significant ATO effect on EWS xenografts (Smith et al., 
2012). As both ATO and GANT61 are known to inhibit GLI1 and GLI2, the different 
results obtained using these two inhibitors were surprising. 
Indeed, all EWS cell lines were significantly more sensitive to ATO in the MTS assay 
than MSC whose viability was barely compromised even using doses as high as 10 µM 
ATO. This indicates that ATO presents a high specificity for EWS cells. Both A673 and 
RD-ES acquired IC50 values blow 2 µM, whereas SK-N-MC cells were more resistant 
with a half maximal inhibitory concentration of 4.42 µM. Equal results concerning A673 
and RD-ES were made by Beauchamp et al. with ATO in a WST-1 viability assay were 
both cell lines reached IC50 values below 1 µM (Beauchamp et al., 2011). Comparable 
results with ATO were also demonstrated previously with RMS cell lines in comparison 
to primary skeletal muscle cells (SKMC) in the laboratory of cell biology of the 
department of orthopaedic surgery (Boehme et al., 2016 (2)).  
Concerning colony formation, doses of ATO required for significantly compromised 
colony formation were only slightly lower compared to the MTS assay. In 3D spheroid 
culture already the use of 2 µM ATO resulted in a sufficient growth inhibition and 
destabilisation of A673 and SK-N-MC cultures. To investigate the ability of ATO to 
induce cell death in EWS cell lines flow cytometry analysis was performed. Cell death 
was highly present in all EWS cell lines, whereas MSC presented no dying cells. 
However, SK-N-MCs needed 5 µM ATO for high rates of cell death which is the maximal 
achieved plasma level for ATO in leukaemia patients (Au et al., 2008). To confirm that 
cell death was actually caused by apoptosis, levels of cleaved PARP and cleaved      
caspase 3 were analysed and quantified. ATO induced caspase 3 dependent apoptosis 
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both in A673 and SK-N-MC cells. However, neither cleaved PARP nor cleaved       
caspase 3 was detected in ATO treated RD-ES cells, which were nevertheless dying as 
determined by loss of membrane integrity. This indicates that induction of apoptosis upon 
ATO in RD-ES could be dependent on other caspases or that RD-ES turn to necrosis 
instead. Furthermore, Kondo et al. provided evidence that the apoptosis-inducing factor 
(AIF), which is commonly known to be released from the mitochondria by PARP can 
also be induced PARP-independently in neuronal cells by α-eleostearic acid (α-ESA), a 
trienoic fatty acid and thereby induce apoptosis independently of PARP (Kondo et al., 
2010).  Further experiments are required for investigating this. 
The high sensitivity of the EWS cell lines to ATO, whereas GANT61 was neither efficient 
nor selective, cannot be explained by GLI protein expression. It is possible that EWS are 
more dependent on GLI1 and GLI2 protein function compared to MSC. However, both 
inhibitors target GLI proteins. Therefore, off target effects of ATO might be involved the 
high sensitivity of the EWS cell lines and their individual reaction to ATO. So far MAPK 
inhibition, breakdown of mitochondrial membrane potential and subsequent ROS release 
leading to apoptosis, necrosis, autophagy or differentiation have been found to be 
influenced by ATO (Mathieu and Besancon, 2006; Zhao et al., 2015). Also discussed as 
potentially involved in differential ATO response is the expression of aquaporin 9 
(AQP9), a water-selective membrane channel responsible for the uptake of ATO into the 
cell. Therefore, cells with high expression of AQP9 can be more sensitive to the drug 
(Iriyama et al., 2013; Leung et al., 2007). Additionally, p53 mutations detected in all of 
the EWS cell lines examined and loss of p16/p14 in A673 cells may interfere with drug 
sensitivities and the ability to undergo apoptosis (May et al., 2013). Differences in the 
degradation and secretion of ATO as well as further targets could also play a significant 
role. As shown by Mathieu and Besancon as well as Zhang et al. the EWS-FLI1 fusion 
protein abundance was not affected by ATO application (Mathieu and Besancon, 2006; 
Zhang et al., 2012). The wide range of possible causes for the contradictory sensitivity of 
the EWS cell lines to GANT61 and ATO and their correlation to GLI1 and GLI2 protein 
expression need to be further investigated. 
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4.3 Etoposide and doxorubicin sensitivity of Ewing sarcoma cells 
4.3.1 Etoposide 
As shown in previous studies etoposide treatment of HeLa cells and in vivo experiments 
with human tumour cells treated with etoposide, led to cell cycle arrest and therefore 
inhibition of proliferation (Loike and Horwitz, 1976a; Loike and Horwitz, 1976b; 
Stahelin, 1973). I treated three EWS cell lines (A673, RD-ES and SK-N-MC) as well as 
healthy MSC with a range of etoposide concentrations between 0.5 µM and 10 µM. The 
EWS cell lines all showed a significant decrease in viability with IC50 values ranging 
between 0.88 µM (A673) and 1.11 µM (SK-N-MC), with A673 cells being the most 
sensitive, whereas MSC seemed to be largely resistant to all etoposide doses applied. A 
study by May et al. also using A673 and SK-N-MC cells, shows similar results concerning 
the sensitivity of these two cell lines to etoposide. In a DIMSCAN cytotoxicity assay    
IC99 values of SK-N-MC (~6.8 µM etoposide) and A673 (<0.2 µM etoposide) showed 
that A673 cells are significantly more sensitive to etoposide than SK-N-MC (May et al., 
2013). In this work the difference between A673 and SK-N-MC cells was not as 
significant, which could be due to the different assays used. However, all EWS cell lines 
were sensitive to etoposide in comparison to the slow growing MSC, which confirms that 
etoposide primarily targets fast growing cells.  
Considering colony formation (chapter 3.3.2), A673 cells were less sensitive than RD-ES 
and SK-N-MC. However, all EWS cell lines already showed significantly reduced colony 
formation with lower doses of etoposide compared to MTS assays. These results are in 
agreement with previous studies using EWS (Fong et al., 2013) where it has been shown 
that the gene expression profile can vary with cell density. Therefore, lower cell densities 
as present in the clonogenic assay may increase sensitivity towards etoposide, whereas 
higher cell densities such as in the MTS assay may lead to lower drug sensitivity 
compared to colony formation. Moreover, MTS assays measure the activity of cellular 
metabolism in a collective of cells, whereas colony formation assays determine the ability 
of individual cells to proliferate and not only to survive.  
Even higher etoposide concentrations up to 2 µM were needed for a significant 
suppression of growth in 3D spheroid culture of A673 and SK-N-MC. Here, SK-N-MCs 
presented themselves more sensitive to etoposide compared to A673. The increased drug 
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doses needed in 3D growth could be due to decreased drug penetration as well as an 
increase of cell-cell contacts in 3D structure, leading to mediation of pro-survival signals 
and less contact to the culture medium. 
Proliferation and viability were reduced by etoposide in all EWS cell lines examined. 
Etoposide as a chemotherapeutic agent is interacting with topoisomerase II in 
proliferating cells. This leads to cell cycle arrest and an accumulation of DNA strand 
breaks which then activate the apoptotic pathway (Karpinich et al., 2002; Meresse et al., 
2004). To examine the induction of cell death in etoposide-treated cells two methods were 
used. With flow cytometry the uptake of the fluorescent dye eFluor ® 450 was measured 
confirming the destabilisation of the cell membrane (compare chapter 3.5.1). 
Furthermore, to confirm that apoptosis was occurring, the amount of cleaved caspase 3 
and cleaved PARP was analysed using western blot (compare chapter 3.5.2). With more 
than 50 % eFlour® 450 positive cells after treatment with 1 µM etoposide, A673 cells 
presented themselves as the most sensitive in flow cytometry. Both RD-ES and               
SK-N-MC also showed etoposide induced dye uptake, whereas the cell membrane in 
MSC appeared to be unaffected by any of the etoposide doses applied. Apoptosis could 
be confirmed in all three EWS cell lines, by both PARP and caspase 3 cleavage. In MSC 
cleaved caspase 3 was hardly detectable and only low amounts of higher molecular weight 
bands running above 116 kDa were found with the PARP antibody. As the molecular 
weight of full length PARP is 116 kDa these bands may represent binding of full length 
PARP or unspecific binding by the PARP antibody. Interestingly, these bands are only 
present in MSC samples, regardless of the substance used, which could indicate a 
modification in the antibody binding site of the full length PARP in MSC which permits 
binding in the absence of cleavage. Altogether, etoposide induced reduced proliferation 
and viability as well as apoptosis could be observed in all three EWS cell lines, whereas 
MSC seemed to be largely unaffected. 
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4.3.2 Doxorubicin 
As shown in previous studies treatment of cells with doxorubicin inhibits nuclear DNA 
replication and RNA synthesis by binding of topoisomerase II, thus equally to etoposide 
leading to a cell cycle arrest and subsequent apoptosis (Minotti et al., 2004; Potmesil et 
al., 1984). The EWS cell lines and MSC were treated with a range of doxorubicin doses 
between 10 nM and 120 nM, resulting in a significant decrease of EWS cell viability with 
IC50 values ranging between 27.18 nM (A673) and 115 nM (RD-ES). Although, treatment 
with 150 nM doxorubicin also reduced the viability of MSC to 68.6 %, all EWS cell lines 
were more sensitive. A study by May et al. also using A673 and SK-N-MC cells, shows 
similar results concerning the range of doxorubicin applied in these two cell lines. In their 
cytotoxicity assay IC99 values of SK-N-MC (~12.0 nM doxorubicin) and A673           
(~21.7 nM doxorubicin) showed that there SK-N-MC were slightly more sensitive than 
A673 (May et al., 2013), whereas in this work A673 were the most sensitive EWS cell 
line to doxorubicin. During colony formation doxorubicin affected all three EWS cell 
lines to the same extent with only 15 nM doxorubicin being sufficient to inhibit colony 
formation completely which is significantly below the IC50 values achieved in the MTS 
assay. As with etoposide (compare chapter 4.3.) the lower cell densities in the clonogenic 
assay may contribute to the increased sensitivity towards doxorubicin compared to the 
sensitivity in the MTS assay with higher cell densities. Similar again to etoposide, higher 
doxorubicin concentrations up to 50 nM were needed for a significant suppression of 3D 
spheroid culture growth of SK-N-MC and A673, as drug penetration of cells in 3D 
structure can be reduced due to a smaller outside-surface as well as different cell-cell 
contacts (Fong et al., 2013). Interestingly, A673 cell were significantly less sensitive to 
doxorubicin compared to SK-N-MC in 3D spheroid cultures in contrast to viability assays 
and colony formation assays. Both flow cytometry analysis and western blot were again 
used for confirmation of cell death and apoptosis. In accordance with the viability assay 
A673 cells presented themselves as most sensitive to doxorubicin in flow cytometry. Both     
RD-ES and SK-N-MC also showed dose dependent doxorubicin-induced dye uptake, 
whereas the cell membranes of MSC appeared to be unaffected by any doxorubicin doses 
applied. The restricted viability reduction of the SK-N-MC cell line compared to A673 
might be explained by a previous doxorubicin treatment of the patient from whom           
SK-N-MCs were obtained (May et al., 2013). However, RD-ES cells showed an even 
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more limited response in the MTS assays, while previous doxorubicin treatment is not 
reported for the donor of RD-ES. Only A673 cells presented clear cleaved PARP and 
caspase 3 bands whereas traces of cleaved PARP and caspase 3 could be found in RD-ES 
and SK-N-MC. However, quantification normalised to tubulin expression showed low 
amounts of cleaved caspase 3 and PARP induction in all EWS cell lines especially using 
the higher dose of 50 nM doxorubicin. In MSC cleaved caspase 3 was barely detectable 
and only the previously described low amounts of a higher molecular weight band running 
with the PARP antibody were found. Altogether, reduced proliferation and viability as 
well as induced cell death could be observed in all three EWS cell lines. Apoptosis by 
means of cleaved PARP or cleaved caspase 3 was present in all three EWS cell lines. But 
also other mechanisms might contribute to cell death induction. 
 
4.4 Effectiveness of ATO combinations with the cytostatics etoposide 
and doxorubicin 
As multidrug resistance occurs in 30 % of patients with localised EWS after first line 
treatment further therapeutic options are required (May et al., 2013). Development of 
multidrug resistance is based on several cellular events such as enhanced repair of damage 
and thereby inhibition of apoptosis or failure to undergo cell cycle arrest, enhancing the 
efflux or exclusion of the applied cytostatic drug as well as their degradation, failure to 
activate prodrugs or alterations of the drug targets (Melguizo et al., 2011; Tan et al., 
2000). One of the mechanism increasing the efflux of drugs overexpression of multidrug 
transporters such as MRP1 which is also known to be abundantly expressed in EWS (Oda 
et al., 1997) and also in all three EWS cell lines used in this work (Boehme et al., 2016 
(1)). Furthermore, MRP1 can be transcriptionally targeted by GLI1 (Santisteban, 2010), 
which leads to the assumption that GLI1 inhibition could reduce MRP1 expression and 
therefore reverse resistance of EWS cells to MRP1 substrates such as etoposide or 
doxorubicin which were both used in this work. 
Since GANT61 was not inducing cell death and additionally was not selective between 
MSC and the EWS cell lines tested concerning viability reduction, it was excluded from 
combination experiments. ATO significantly and specifically compromised viability, 
colony formation and growth in 3D culture as well as apoptosis induction. Additionally, 
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ATO has already been shown to reduce doxorubicin resistance in osteosarcoma by 
downregulation of stathmin expression (Feng et al., 2014) which is a regulatory protein 
in the assembly of the mitotic spindle (Rubin and Atweh, 2004). Furthermore, first 
potential additive effects were described after a combination with etoposide in EWS 
patients (Guo et al., 2006). Interestingly, the Arsenic-GSH conjugate is itself a substrate 
to MRP1 which means that MRP1 overexpression might also lead to resistance against 
ATO (Leslie et al., 2004). Therefore, ATO was combined with both etoposide and 
doxorubicin and potential additive effects were examined. Based on the individual drug 
sensitivities of each cell line the doses for combined treatment were selected and applied 
in different combinations. 
Upon combination of etoposide with ATO the viability assay showed additive effects in 
all three EWS cell lines tested, whereas MSC were barely compromised. However, 
sensitivity to the individual drugs and combinatorial effects differed between the cell 
lines. In RD-ES and SK-N-MC cells 0.5 µM etoposide combined with ATO were 
sufficient to decrease viability significantly compared to single treatment and showed 
similar results in cell death analysis. A673 being extremely sensitive to ATO showed no 
significant cell death induction with 0.1 µM ATO combined with 1 µM etoposide. 
However, viability was significantly reduced. Furthermore, suppression of colony 
formation was reinforced in all three EWS cell lines with a combination of etoposide and 
ATO in comparison to single treatment. However, for an exact statement concerning 
significance, a quantification of colony growth would be necessary. Summarised, the 
combination of etoposide and ATO potentiated the effect of single treatments with 
etoposide or ATO in the EWS cell lines, only concerning cell death in A673 cell the effect 
of etoposide dominated.  
Combined treatment of the EWS cell lines with doxorubicin and ATO significantly 
potentiated the suppression of colony formation achieved by single drug application. In 
addition, slightly additive effects on the inhibition of viability in all three EWS cell lines 
could be observed, whereas MSC again were barely compromised. Cell death was only 
efficiently increased compared to single treatment in A673 cells with the combination of 
5 nM doxorubicin and 0.3 µM ATO, whereas RD-ES and SK-N-MC cells did not present 
any additive effects concerning loss of membrane integrity.  
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A triple treatment with both etoposide and doxorubicin as well as ATO could neither 
clearly enhance cell death nor compromise viability further compared to the combination 
of two drugs. However, later experiments in the laboratory achieved lowest number of 
colonies after application of the triple treatment in RD-ES and SK-N-MC (Boehme et al., 
2016 (1)). 
 
4.5 Conclusion and future outlook 
In this work it could be shown that the EWS cell lines A673, RD-ES and SK-N-MC were 
highly sensitive to ATO which is known to inhibit GLI1 and GLI2. However, none of the 
EWS cell lines showed an over-expression of GLI1 or GLI2 protein compared to MSC, 
indicating that EWS are highly dependent on the small amount of residual GLI proteins 
or that off target effects of ATO may play a significant role. Moreover, the second GLI 
inhibitor GANT61 was inefficient, also indicating that GLI inhibition in these EWS cell 
lines might not be crucial, leading to the assumption that ATO might also work by other 
means. Off target effects of ATO may include interactions with different zinc finger 
proteins leading to an inhibition of tumour growth in APL (Nasr et al., 2008). 
Furthermore, ATO also inhibits MAPK and leads to ROS release from the mitochondria 
(Mathieu and Besancon, 2006; Zhao et al., 2015). For further investigation of the 
mechanism of action of ATO in EWS as well as the crosslink to etoposide and 
doxorubicin sensitivity, a wider spectrum of EWS cell lines would be of interest where 
also ROS release, MAPK inhibition and influence on drug transporter expression should 
be analysed. Especially, the application of ATO in combination with etoposide presented 
additive effects in RD-ES and A673 cell lines, so that this combination may be an option 
for chemo-resistant EWS in vivo, which should be tested in a mouse model. Negative 
side-effects could be reduced by combination as individual drug doses could be 
diminished. So far, the combination of etoposide and doxorubicin was not analysed in 
comparison. To rule out that effects seen upon triple treatment are mainly mediated by 
this combination it should be included in further analysis. In the meantime, combination 
treatment was also tested in 3D spheroid cultures showing that the impact of etoposide is 
dominating (Boehme et al., 2016 (1)). As the effect of applied drugs in the spheroid 
cultures was so far only evaluated by shape, size and surface integrity a quantitative 
analysis of the viability of all cells in the spheroids should be strived for. This could be 
obtained by measuring the acid phosphatase enzyme activity using 4-nitrophenyl 
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phosphate as described by Friedrich et al. (Friedrich et al., 2009; Ivanov et al., 2014). The 
spheroid assay has presented a first simulation of the conditions inside a tumour. Another 
aspect of 3D growth is hypoxia, which still has to be examined with the EWS cell lines 
and the drugs etoposide, doxorubicin and ATO as well as with in vivo experiments after 
that.  
Furthermore, etoposide and doxorubicin are only two of several cytostatic drugs which 
are used in therapy for EWS. Vincristine also belonging to the standard first line therapy 
in Europe for localised EWS (Balamuth and Womer, 2010; Juergens et al., 2006) could 
be included in experiments with ATO combination as well as cyclophosphamide and 
ifosfamide, which may be investigated in in vivo experiments as they, being anticancer 
prodrug substances metabolised by several P450 enzymes, cannot be activated during in 
vitro culture (Chen et al., 2004). Furthermore, the mode of action connecting decreased 
chemo-resistance with ATO is of future interest. Therefore, chemo-resistant cell lines, for 
instance generated by gradually increasing drug doses over months should also undergo 
ATO treatment. Furthermore, the expression of ABC transporters in EWS cell lines 
compared to MSC should be tested after application of ATO both at mRNA and protein 
levels. Thereby, MRP1 is of special interest as it is known to be aberrantly expressed in 
EWS and is a target of GLI1 (Boehme et al., 2016 (1); Santisteban, 2010). Moreover, the 
ABC transporters ABCA6 and ABCA7 also play a role in EWS progression (Pasello, 
2015) as well as MDR1 (Oda et al., 1997) and potential changes of expression upon ATO 
treatment are possible. Furthermore, cell lines with an inherent or experimentally induced 
over- or under-expression of these transporters could be selectively tested on any 
correlating resistances against etoposide and doxorubicin as well as the ability of ATO to 
reduce these in combined treatment. Therefore, knockdown experiments targeting these 
transporters in the EWS cell lines could be used. Possibly, also a combination with other 
substances tested for targeted therapy in EWS might show further additive effects. 
Currently, substances targeting the epidermal growth factor, vascular growth factor 
receptors, mammalian target of rapamycin, IGF1R, PARP1 and EWS-FLI1 are all in 
clinical or preclinical testing (Bagatell et al., 2014; Daw et al., 2005; Fox et al., 2010; 
Jiang et al., 2015b; Schwartz et al., 2013). 
For more exact insights in the conditions inside the tumour and before potential clinical 
testing, drug combinations should be analysed in vivo. A mouse model has already been 
established by Beauchamp et al. (Beauchamp et al., 2011). 
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5 Abstract 
Ewing sarcoma (EWS) are mesenchymal tumours usually occurring in children and 
adolescents. Currently, patients with non-metastatic EWS show 5-year survival rates 
above 70 % when treated radically with surgery, chemotherapy and radiotherapy, whereas 
relapsed or metastasised EWS are more difficult to treat. One of many reasons is the 
increasing drug resistance in relapsed EWS including the expression of ABC transporters 
such as PGP or MRP1 which transport cytostatic drugs back through the cell membrane 
into the extracellular matrix. Furthermore, EWS express the characteristic EWS-FLI1 
fusion protein which also modulates the GLI proteins in the Hedgehog (Hh) pathway. 
Aberrant Hh-signalling has been observed in several malignancies including EWS and 
correlates with cancer formation and progression. As the Hh pathway directly targets 
expression of ABC transporter proteins, GLI inhibition as additional therapeutic option 
to overcome multi drug resistance was investigated. In the present study viability, colony 
formation, growth of 3D cultures and induction of cell death was analysed in three EWS 
cell lines treated with the GLI inhibitors GANT61 and ATO as well as the established 
cytostatics etoposide and doxorubicin using MTS assay, clonogenic assay,  3D spheroid 
assay, flow cytometry and western blot. ATO, etoposide and doxorubicin reduced 
viability significantly and selectively in all three EWS cell lines in comparison to 
mesenchymal stem cells (MSC). On the other hand, GANT61 was less efficient in two of 
three EWS cell lines and particularly not selective compared to MSC. Cell death was 
induced by ATO, etoposide and doxorubicin in all three EWS cell lines, but not MSC. 
The combination of ATO and etoposide potentiated this effect. The combined application 
of ATO and doxorubicin also significantly compromised viability compared to individual 
treatment. However, a triple combination of ATO with both cytostatics did not 
compromise cells more than the double combinations. The present results indicate that 
ATO is effective in EWS. Therefore, ATO may contribute to increased survival rates of 
patients with EWS and especially reduce resistance of aggressive EWS against 
chemotherapeutics. Furthermore, as doses for drugs can be reduced in combined 
treatment, adverse effects of chemotherapy may be diminished. However, further 
evaluation of the detailed inhibitory mechanisms in EWS is needed before transferring 
this approach to the clinic. 
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6 Zusammenfassung 
Ewing Sarkome (EWS) zählen zu den mesenchymalen Tumoren und treten gehäuft bei 
Kindern und Jugendlichen auf. Patienten mit nicht-metastasiertem EWS, die sich einer 
radikalen chirurgischen Intervention, Radiotherapie und/oder Chemotherapie 
unterziehen, zeigen eine durchschnittliche 5-Jahres Überlebensrate von über 70 %, 
wohingegen metastasierte und rezidivierte EWS deutlich schwerer zu behandeln sind. 
Einer der vielen Gründe dafür ist die zunehmende Resistenz von rezidivierten EWS gegen 
Chemotherapeutika. Diese beruht unter anderem darauf, dass ABC Transporter wie PGP 
oder MRP1, welche die Chemotherapeutika wieder aus der Tumorzelle in den 
Extrazellularraum befördern, von diesen exprimiert werden. Darüber hinaus wird vom 
EWS das für den Tumor charakteristische Fusionsprotein EWS-FLI1 exprimiert, welches 
auch die GLI Proteine im Hedgehog (Hh) Signalweg moduliert. Veränderungen im Hh 
Signalweg wurden bereits in verschiedenen Tumoren beobachtet und korrelieren mit 
einer erhöhten Tumorbildung und Progression. Da der Hh Signalweg direkt die 
Expression von ABC Transportern beeinflusst, wurde in dieser Arbeit die Inhibition der 
GLI Proteine als mögliche zusätzliche Therapieoption zur Unterdrückung der 
Chemoresistenz getestet. Dafür wurden drei EWS Zelllinien mit den GLI Inhibitoren 
GANT61 und ATO, sowie den bereits etablierten Chemotherapeutika Etoposid und 
Doxorubicin behandelt und ihre Viabilität, Koloniebildungsfähigkeit, Wachstum in 3D 
Kulturen und Induktion von Zelltod mittels MTS Assay, Koloniebildungs-Assay,            
3D Spheroid Assay, Durchflusszytometrie und Western Blot getestet. ATO, Etoposid und 
Doxorubicin reduzierten die Viabilität signifikant und selektiv in allen drei EWS 
Zelllinien im Vergleich zu mesenchymalen Stammzellen (MSC). Dahingegen war 
GANT61 weniger effizient in zwei der drei EWS Zelllinien und vor allem nicht selektiv 
gegenüber MSC. Zelltod konnte durch ATO, Etoposid und Doxorubicin in allen EWS 
Zelllinien, nicht aber in MSC induziert werden. Dieser Effekt wurde mit der Kombination 
von ATO und Etoposid noch einmal potenziert. Die Kombination von ATO und 
Doxorubicin reduzierte die Viabilität ebenfalls signifikant, verglichen mit der Einzelgabe. 
Eine dreifache Kombination aus ATO, Etoposid und Doxorubicin zeigte jedoch keinen 
zusätzlichen Nutzen im Vergleich zu den Zweifach-Kombinationen. Die bisherigen 
Ergebnisse deuten darauf hin, dass ATO zur Erhöhung der Überlebensraten von EWS 
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Patienten und zur Reduzierung von Resistenzen gegen Chemotherapeutika in aggressiven 
EWS beitragen kann. Durch die reduzierte Dosis der kombinierten Substanzen können 
Nebenwirkungen der Chemotherapeutika vermindert werden. Vor einem potenziellen 
klinischen Einsatz werden allerdings weitere Informationen über die detaillierten 
Wirkmechanismen in EWS benötigt. 
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